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VILLANOVA LAW REVIEW
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Articles
REVERSAL OF FORTUNE: MOVING PHARMACEUTICALS FROM
OVER-THE-COUNTER TO PRESCRIPTION STATUS?
LARS NOAH*
“Reality is just a crutch for people who can’t cope with drugs.”
–Robin Williams†
THE opioid “epidemic” recently has grabbed national attention, withregular headlines about the rising number of overdose deaths related
to narcotic painkillers, though most occur when patients transition to il-
licit opiates.1  Our medicine cabinets hold an equally insidious scourge,
however, that gets essentially no attention: nonprescription drugs that
cause tens of thousands of deaths annually.2  As new risks come to light,
the federal government may call for the addition of another line of text on
the increasingly crowded labels of these popular products, but consumer
behavior suggests that most of us remain blissfully unaware of the poten-
tial consequences of our growing dependence on over-the-counter (OTC)
drugs, particularly those that previously required visiting a physician.3
* Stephen C. O’Connell Chair, University Term Professor, and Professor of
Law, University of Florida; author, LAW, MEDICINE, AND MEDICAL TECHNOLOGY
(Foundation Press 4th ed. 2017).
† Behind the Laughter Was a Harsh Reality; Robin Williams 1951-2014, TORONTO
STAR, Aug. 12, 2014, at A1 (calling this “possibly the most famous of his many
classic one-liners”).
1. See, e.g., Robert J. Blendon & John M. Benson, The Public and the Opioid-
Abuse Epidemic, 378 NEW ENG. J. MED. 407 (2018); Lawrence O. Gostin et al., Re-
framing the Opioid Epidemic as a National Emergency, 318 JAMA 1539 (2017); Joel
Achenbach et al., Opioid Crisis Is a National Emergency, President Says, WASH. POST,
Aug. 11, 2017, at A1; Lenny Bernstein & Christopher Ingraham, Drug Crisis Fuels
Drop in At-Birth Life Expectancy, WASH. POST, Dec. 21, 2017, at A20.
2. See Lars Noah, Challenges in the Federal Regulation of Pain Management Technol-
ogies, 31 J.L. MED. & ETHICS 55, 62 (2003) (explaining that nonsteroidal anti-in-
flammatory drugs (NSAIDs) “may represent a far more serious public health
menace [than opioids], contributing to thousands of patient deaths each year”);
infra Part II.B (elaborating); see also infra Part III (discussing the litany of serious
hazards associated with other types of popular OTC drug products).
3. See Jane E. Brody, The Large, Perhaps Outsize, Role of O.T.C.s, N.Y. TIMES, Dec.
1, 2015, at D5.
(355)
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American consumers spent over $34 billion on OTC drugs in 2017.4
Although that amounts to less than ten percent of annual prescription
(Rx) drug sales,5 dramatic price differentials between these two categories
of products mean that roughly comparable volumes get used.6  Demands
continue to grow for expanded access to pharmaceuticals without first hav-
ing to secure a prescription from a physician.7  More often than not, the
U.S. Food and Drug Administration (FDA) has obliged, allowing a num-
ber of drugs to switch to OTC status.8  As the agency once explained, non-
prescription medications “have an increasingly vital role in the U.S. health
care system by providing consumers easy access to certain drugs that can
be used safely for conditions that consumers can self-treat without the
help of a health care practitioner.”9
Although generally greeted with enthusiasm from all concerned, Rx-
to-OTC switches do not represent an unalloyed good.  In particular, con-
sumers may utilize these increasingly powerful therapeutic agents in far
4. Consumer Healthcare Products Association (CHPA), OTC Retail Sales
1964–2017, https://chpa.org/OTCRetailSales.aspx [https://perma.cc/R5UP-
PECX] (last visited Apr. 4, 2018).
5. See Robert Pear, U.S. to Test Ways to Cut Drug Costs in Medicare, N.Y. TIMES,
Mar. 9, 2016, at A14 (reporting that Americans spent $457 billion on prescription
drugs in 2015).
6. Compare CHPA, OTC Sales in Volume, https://www.chpa.org/OTCSales-
Volume.aspx [https://perma.cc/G2EX-HVZL] (last visited Apr. 9, 2018) (showing
that almost 5.9 billion units were sold in 2017), with Jeff Donn, Are We Taking Too
Many Drugs?, NEWSDAY, Apr. 19, 2005, at B13 (reporting that Americans fill 3.5
billion prescriptions annually).
7. See Peter Temin, Realized Benefits from Switching Drugs, 35 J.L. & ECON. 351,
352 (1992) (“Concern about the rising cost of medical care has been joined by
suspicion of government regulation to create a movement to revive self-
medication.”).
8. See, e.g., Serena Gordon, Sniffing out the Best Allergy Treatment; For Most 12
and Older, Nasal Sprays Are the Way to Go, CHI. TRIB., Dec. 27, 2017, at D2 (reporting
that steroid intranasal sprays such as Flonase® and Nasonex® have now joined
other nonsedating antihistamines switched OTC such as Allegra®, Claritin® and
Zyrtec®); see also David A. Grimes, Switching Emergency Contraception to Over-the-
Counter Status, 347 NEW ENG. J. MED. 846, 846 (2002) (“In the past 30 years, over
700 products have been switched from prescription to over-the-counter status.  Re-
cent examples include tioconazole, cromolyn sodium, bentoquatam, triclosan, and
nicotine polacrilex.”); FDA, Prescription to Over-the-Counter (OTC) Switch List, https:/
/www.fda.gov/aboutfda/centersoffices/ officeofmedicalproductsandtobacco/
cder/ucm106378.htm [https://perma.cc/CJS2-CPTV] (last visited Feb. 2, 2018).
9. Public Hearing, Over-the-Counter Drug Products, 65 Fed. Reg. 24,704,
24,705 (Apr. 27, 2000); see also id. (“Consumers have access to more than 100,000
OTC drug products encompassing more than 800 active ingredients and covering
more than 100 therapeutic categories or classes.”); Innovative Approaches for
Nonprescription Drug Products; Draft Guidance for Industry, 83 Fed. Reg. 33,938,
33,939 (July 18, 2018) (“FDA believes the innovative approaches described in this
draft guidance could lead to the approval of a wider range of nonprescription
drug products. FDA currently intends to issue a proposed rule that provides more
details regarding the use of additional conditions for [consumer access to OTC]
products.”).
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too cavalier a fashion.10  In addition, researchers have discovered a grow-
ing number of serious risks associated with some popular OTC drugs even
when used appropriately.  The FDA, however, seems unwilling to switch
these products back to prescription status, preferring instead to handle
newly discovered hazards with revisions in labeling.  This Article evaluates
the reasons for—and the public health consequences of—this reticence to
reverse such switches before suggesting that enhanced exposure to tort
liability may help prompt sellers to take the initiative.
Part I offers the necessary background about this regulatory arena,
first identifying the standards used by the FDA in drawing the prescrip-
tion/nonprescription line, and then explaining the two basic procedures
available for introducing an OTC drug product.  Part II focuses on the
experience with internal analgesics, in order to briefly illustrate the previ-
ously discussed mechanics for making Rx-to-OTC switches before elaborat-
ing on the subsequently identified hazards with these products and the
agency’s generally tepid responses.  Part III expands upon this rogues’ gal-
lery, identifying other popular nonprescription products that show no sign
of returning to prescription status in spite of mounting safety concerns.
Part IV asks what accounts for this reluctance to shift dangerous products
back and whether either legislative intervention or the threat of tort liabil-
ity might serve as necessary counterweights.  Ultimately, the Article con-
cludes on a fairly pessimistic note about the prospects for confronting this
country’s underappreciated drug problem.
I. CRITERIA AND METHODS FOR SWITCHING DRUGS
TO NONPRESCRIPTION STATUS
The decision over whether a prescription drug can switch to nonpre-
scription status has become increasingly contested.11  When it passed the
federal Food, Drug, and Cosmetic Act (FDCA) in 1938,12 Congress drew
10. See Sandra G. Boodman, Painful Choices: Consumers Face a Baffling Wall of
Choices—and a Surprising Number of Serious Risks—When They Seek Relief from Minor
Pains and Illnesses in the Drug Aisle, WASH. POST, Feb. 11, 2003, at F1; infra note 80
and accompanying text.
11. See Eric P. Brass, Changing the Status of Drugs from Prescription to Over-the-
Counter Availability, 345 NEW ENG. J. MED. 810, 812-15 (2001); Brian L. Strom, Sta-
tins and Over-the-Counter Availability, 352 NEW ENG. J. MED. 1403, 1403-05 (2005);
Gina Kolata, There’s a Blurry Line Between Rx and O.T.C., N.Y. TIMES, Dec. 21, 2003,
§ 4, at 3; Sheryl Gay Stolberg, F.D.A. Considers Switching Some Prescription Drugs to
Over-the-Counter Status, N.Y. TIMES, June 28, 2000, at A18; see also Lars Noah, Treat
Yourself: Is Self-Medication the Prescription for What Ails American Health Care?, 19
HARV. J.L. & TECH. 359, 391-92 (2006) (“The choice between prescription and
OTC distribution for a pharmaceutical product is nothing to sneeze at.  Apart
from the potentially enormous financial stakes for all involved—manufacturers,
health insurers, and patients/consumers—the classification could have profound
public health consequences . . . .”); infra note 50 (discussing the battle over switch-
ing emergency contraception).
12. Pub. L. No. 75–717, 52 Stat. 1040 (1938) (codified as amended at 21
U.S.C. §§ 301–396 (2012)).
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no distinction between prescription and OTC pharmaceuticals,13 and it
apparently had “not intended to restrict in any way the availability of drugs
for self-medication.”14  Nonetheless, when the FDA issued regulations to
implement the new legislation later that year, it for the first time provided
that certain drugs could not be sold directly to consumers.15  Six years
later, the agency promulgated a rule designating a class of drugs that
would be safe only when used “by or under the supervision of a physi-
cian.”16  In one early enforcement case, the FDA successfully prosecuted a
seller of testosterone products for making these available as nonprescrip-
tion drugs.17
In 1951, the very same year that this case concluded, Congress ex-
pressly demarcated prescription drugs as a separate category when it
passed the Durham-Humphrey Amendment.18  New section 503(b)(1) of
the FDCA provided in relevant part that a drug, which “because of its tox-
icity or other potentiality for harmful effect, or the method of its use, or
the collateral measures necessary to its use, is not safe for use except
under the supervision of a practitioner licensed by law to administer such
drug, . . . shall be dispensed only” upon a prescription.19  The statute also
13. It had, however, exempted drugs prescribed by a health professional from
certain misbranding prohibitions. See id. § 503(b), 52 Stat. 1052 (codified as
amended at 21 U.S.C. § 353(b)(2)).
14. H.R. REP. NO. 75–2139, at 8 (1938), quoted in United States v. Articles of
Drug, 625 F.2d 665, 672 (5th Cir. 1980).  “On the contrary, it [wa]s intended to
make self-medication safer and more effective.” Id.
15. See Promulgation of Regulations Under the Federal Food, Drug, and Cos-
metic Act, 3 Fed. Reg. 3161, 3168 (Dec. 28, 1938) (appearing as subsection (b)(2)
of the rule implementing FDCA § 502(f)); see also Peter Temin, The Origin of Com-
pulsory Drug Prescriptions, 22 J.L. & ECON. 91, 98–100, 103–05 (1979) (criticizing this
development).
16. See Regulations for the Enforcement of the Federal Food, Drug, and Cos-
metic Act, 9 Fed. Reg. 12,255, 12,255–56 (Oct. 10, 1944) (codified at 21 C.F.R.
§ 2.106(b) (1950)); see also Peter Barton Hutt, A Legal Framework for Future Decisions
on Transferring Drugs from Prescription to Nonprescription Status, 37 FOOD DRUG COSM.
L.J. 427, 431–32 (1982) (discussing this regulation).
17. See United States v. El-O-Pathic Pharmacy, 192 F.2d 62, 74–78 (9th Cir.
1951).  Even as approved prescription drugs, testosterone products continue to
trouble the FDA. See Sabrina Tavernise, Drugs Using Testosterone Will Label Heart
Risks, N.Y. TIMES, Mar. 4, 2015, at A16 (“[M]anufacturers of testosterone drugs
used by millions of Americans will be required to change labels for the drugs to
warn that they could increase the risk of heart attacks and strokes and should not
be prescribed to treat symptoms in men brought on by age, such as declining sex-
ual drive.”); Steven Woloshin & Lisa M. Schwartz, Opinion, Sell the Disease to Sell the
Drug, WASH. POST, June 8, 2015, at A15 (“Why are so many men taking testosterone
for an unapproved use?  The nearly tenfold increase in testosterone prescriptions
began in 2007 when Abbott Laboratories (now AbbVie) launched its award-win-
ning ‘Is It Low-T?’ disease awareness campaign.”).
18. See Pub. L. No. 82–215, § 1, 65 Stat. 648 (1951) (codified as amended at
21 U.S.C. § 353(b)).  Industry representatives opposed an earlier version of this
legislation for granting the FDA greater authority to decide which drugs would
require a prescription. See Temin, supra note 15, at 102–03.
19. 21 U.S.C. § 353(b)(1)(A) (2012).  A new drug may have to abide by pre-
scription-only availability if so provided in its labeling at the time of approval, but
4
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allowed the FDA to exempt drugs from this requirement if it was “not
necessary for the protection of the public health,”20 and a half-century
later the agency controversially asserted the power to do so even in the
face of objections by the manufacturer of a prescription drug.21
When it considers an application for approval of a new drug, the FDA
must decide whether to restrict access to it.  At least initially, virtually all
new ingredients are made available only upon a prescription from—or
through direct administration by—a licensed health care professional
while the FDA collects additional safety data.22  Premature OTC market-
ing would further complicate the already difficult process of collecting ad-
verse event reports; instead of relying on information about side effects
observed in patients while under the supervision of physicians, the agency
would receive sporadic and indiscriminate consumer complaints.23  Only a
the statute does not separately specify what would prompt such a choice. See id.
§ 353(b)(1)(B); see also Lars Noah, Ambivalent Commitments to Federalism in Control-
ling the Practice of Medicine, 53 U. KAN. L. REV. 149, 175–76 (2004) (explaining that
the FDA defers to state judgments about who enjoys prescribing privileges); id. at
179–80 (same, for controlled substances).
20. 21 U.S.C. § 353(b)(3); see also Drug Approvals: Circumstances Under
Which an Active Ingredient May Be Simultaneously Marketed in Both a Prescrip-
tion Drug Product and an Over-the-Counter Drug Product, 70 Fed. Reg. 52,050,
52,051 (Sept. 1, 2005) (explaining that one of Congress’ “primary objectives” was
“to relieve retail pharmacists and the public from burdensome and unnecessary
restrictions on the dispensing of drugs that are safe for use without the supervision
of a physician”).
21. See Marc Kaufman, FDA Says It Can Take Away Drugs’ Prescription Status,
WASH. POST, Apr. 26, 2003, at A1 (“FDA officials . . . rested their conclusion, in
part, on the FDA’s legal authority to regulate the safety of all drugs, including
whether or not they require a doctor’s prescription to ensure the protection of
patients.”).  I did not buy it:
Although this authority would no doubt justify switching an erstwhile
OTC drug to prescription status in light of newly discovered safety con-
cerns, it is difficult to understand how switching from prescription to
OTC status would ever promote the safe use of a drug.  A switch may
serve any number of other valuable ends, and such a move may not pre-
sent any untoward risk to the public health, but, all other things being
equal, is it not inherently (even if only marginally) safer to use a pharma-
ceutical under the supervision of a health care professional?
Noah, supra note 11, at 378; see also id. at 383–91 (elaborating on the possible legal
objections to such a forced switch).
22. See Stephen Paul Mahinka & M. Elizabeth Bierman, Direct-to-OTC Market-
ing of Drugs: Possible Approaches, 50 FOOD & DRUG L.J. 49, 56–57 (1995) (listing the
handful of new drugs approved from the outset without prescription restrictions);
Temin, supra note 7, at 352 (“The burst of technological progress in the drug
industry after the Second World War led to the introduction of many new drugs,
virtually all of which were marketed as prescription drugs.”).
23. See Robin E. Ferner & Keith Beard, Over the Counter Medicines: Proceed with
Caution, 336 BMJ 694, 696 (2008) (“The safety of over the counter medicines has
to be continually reviewed, even though this is difficult in practice.  Since health-
care professionals may not be involved, we have to rely on patients to report ad-
verse effects.”); Strom, supra note 11, at 1403 (“[O]ver-the-counter use renders it
more difficult to study a drug’s effects, since prescription databases can no longer
be used for that purpose.”).
5
Noah: Reversal of Fortune: Moving Pharmaceuticals from over-the-Counter
Published by Villanova University Charles Widger School of Law Digital Repository, 2018
360 VILLANOVA LAW REVIEW [Vol. 63: p. 355
dozen years ago did Congress obligate all manufacturers of nonprescrip-
tion products to report adverse events to the FDA.24  A prescription drug
later switched OTC will have not only survived the agency’s rigorous
premarket review process for new chemical entities but also withstood the
test of time and a second round of FDA scrutiny.25  Even so, the side ef-
fects of some drugs may not come to light until long after initial
approval.26
A. Factors Used in Deciding Suitability for OTC Sale
Although the statute and regulations provide some general criteria
for differentiating between prescription and OTC products, ultimately
that determination must be made on an ad hoc basis and without clear
guidance.27  The 1951 amendment and the FDA’s regulations mention
toxicity, other harmful effects, methods of use, and the need for collateral
measures,28 but they fail to indicate the point at which one or more of
these factors will necessitate prescription-only availability.  Toxicity con-
cerns may relate to either acute or chronic effects, and this factor often
gets operationalized by reference to a product’s “margin of safety” and the
extent to which it needs to be carefully titrated for each patient.29  Other
24. See Dietary Supplement and Nonprescription Drug Consumer Protection
Act, Pub. L. No. 109–462, § 2(a), 120 Stat. 3469, 3469–72 (2006) (codified at 21
U.S.C. § 379aa (2012)); see also Guidance for Industry on Postmarketing Adverse
Event Reporting for Nonprescription Human Drug Products Marketed Without an
Approved Application, 74 Fed. Reg. 34,023 (July 14, 2009) (implementing this
provision).
25. See Over-the-Counter Human Drugs; Proposed Labeling Requirements, 62
Fed. Reg. 9024, 9027 (Feb. 27, 1997).  For instance, in seeking to switch a reduced
dosage version of Xenical® (orlistat) six years after the FDA’s approval of the pre-
scription version, the manufacturer pointed out that 22 million people around the
world had taken the drug and that it had been studied in more than one hundred
clinical trials enrolling approximately 30,000 subjects. See Sally Squires, Weighing a
Pill for Weight Loss, WASH. POST, Jan. 24, 2006, at F1.
26. See infra Parts II.B & III.  In the early 1990s, for example, the FDA received
requests to switch the nonsedating antihistamines Seldane® (terfenadine) and His-
manal® (astemizole) to nonprescription status after several years of prescription
marketing, only to see the products withdrawn because of the belated discovery of
potentially fatal cardiac side effects. See Bruce Ingersoll, FDA Proposes to Force
Seldane Off the Market, WALL ST. J., Jan. 14, 1997, at B1; see also Ferner & Beard,
supra note 24, at 694 (“Safety concerns can emerge with continued use and re-
straints need to be reimposed.  In the UK, the antihistamine terfenadine was re-
classified from prescription only to pharmacy status, only to be switched back again
when its propensity to cause torsade de pointes [a rare type of arrhythmia] was
appreciated.”).
27. See Hutt, supra note 16, at 428–31.  The former chair of the FDA’s Non-
prescription Drugs Advisory Committee published an article identifying a broad
range of issues relevant when considering an Rx-to-OTC switch. See Brass, supra
note 11, at 811–12 (delineating criteria); id. at 812–15 (discussing the broader
potential pros and cons of a switch).
28. See 21 U.S.C. § 353(b)(1) (2012); 21 C.F.R. § 330.10(a)(4)(vi) (2018).
29. See Hutt, supra note 16, at 433–34; Gerald M. Rachanow, The Switch of
Drugs from Prescription to Over-the-Counter Status, 39 FOOD DRUG COSM. L.J. 201,
6
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harmful effects may include the risk of interactions with food or other
drug products and the potential for abuse.30  Methods of use and “collat-
eral measures” may pose questions about the ability of laypersons to self-
diagnose and self-administer as well as the need for periodic clinical moni-
toring.31  No one factor is determinative, however, as a number of ap-
proved OTC products raise toxicity, drug interaction, self-diagnosis, and
method of administration difficulties.32
Ultimately, the decision may turn on whether appropriate labeling
can help to minimize these problems,33 notwithstanding the fact that con-
sumers routinely fail to pay attention to product labels.34  FDA regulations
204–05 (1984); see also Lars Noah, The Coming Pharmacogenomics Revolution: Tailor-
ing Drugs to Fit Patients’ Genetic Profiles, 43 JURIMETRICS J. 1, 7 & n.25 (2002).
30. The risk of abuse has, from the outset, represented one of the primary
rationales for limiting drug products to prescription-only sale.  As originally en-
acted in 1938, the FDCA required a special warning for a list of “habit forming”
drugs, but it exempted them so long as prescribed as not refillable. See Pub. L. No.
75–717, §§ 502(d), 503(b), 52 Stat. 1040, 1050, 1052 (1938) (codified as amended
at 21 U.S.C. §§ 352(d), 353(b)(2) (1994)), repealed by Food and Drug Administra-
tion Modernization Act of 1997, Pub. L. No. 105–115, § 126(b), 111 Stat. 2296,
2327.  Under a different statute, the Drug Enforcement Administration (DEA) can
recommend to the FDA prescription status for an OTC drug with an abuse poten-
tial. See 21 U.S.C. § 829(d).  Schedule V narcotics with only a limited potential for
abuse can remain in OTC status, but a number of states have mandated dispensing
of these drugs only by pharmacists and sometimes only with a physician’s prescrip-
tion. See Gregory M. Fisher, Third Class of Drugs—A Current View, 46 FOOD DRUG
COSM. L.J. 583, 606–07 (1991) (adding that, before passage of the Controlled Sub-
stances Act in 1970, the FDA would handle such concerns by mandating prescrip-
tion status).
31. The agency sometimes worries that symptomatic relief may mask a serious
underlying condition and cause a consumer to delay seeking medical attention.
See, e.g., United States v. Article of Drug . . . Decholin, 264 F. Supp. 473 (E.D. Mich.
1967) (rebuffing efforts to force an OTC product for gastrointestinal distress into
prescription status).
32. See Hutt, supra note 16, at 433–40.  For example, some OTC drug labels
instruct patients to use the product only after having gotten a physician’s diagnosis
of a particular condition. See, e.g., Martin S. Lipsky & Theresa Waters, The “Prescrip-
tion-to-OTC Switch” Movement: Its Effects on Antifungal Vaginitis Preparations, 8
ARCHIVES FAM. MED. 297, 298 (1999).
33. See Hutt, supra note 16, at 438 (“[P]roblems of toxicity, self-diagnosis, and
self-treatment, can either be accentuated by inadequate labeling, or alleviated by
adequate labeling.  Thus, labeling must be regarded as central to all future deter-
minations of prescription/nonprescription status.”).
34. See Coffman v. Keene Corp., 628 A.2d 710, 717 (N.J. 1993) (adopting the
“heeding presumption” for products liability claims in spite of the fact that, “with
the proliferation of warnings in our society, it is nearly impossible to go through a
day without consciously ignoring warnings designed to protect our health and
safety”); Lars Noah, The Imperative to Warn: Disentangling the “Right to Know” from the
“Need to Know” About Consumer Product Hazards, 11 YALE J. ON REG. 293, 381–84
(1994) [hereinafter Noah, The Imperative to Warn]; id. at 320 & n.112, 381-82
nn.443–44, 388 (discussing the FDA’s views about this and related concerns in the
context of OTC drugs).  Indeed, the FDA has lost some of its faith in the ability of
labeling to communicate important new risk information to health care profes-
sionals and threatened to impose more stringent access restrictions. See Noah,
supra note 19, at 188 & n.167; see also id. at 189–91 (elaborating on possible distri-
7
Noah: Reversal of Fortune: Moving Pharmaceuticals from over-the-Counter
Published by Villanova University Charles Widger School of Law Digital Repository, 2018
362 VILLANOVA LAW REVIEW [Vol. 63: p. 355
provide that nonprescription drug labeling must include directions and
warnings “in such terms as to render them likely to be read and under-
stood by the ordinary individual, including individuals of low comprehen-
sion, under customary conditions of purchase and use.”35  In theory,
therefore, the agency would not permit OTC marketing if overly complex
labeling were necessary to ensure safe use, and it once took the position
that any need to disclose serious risks would defeat a product’s eligibility
for nonprescription availability.36  In practice, however, the FDA has re-
quired fairly detailed labeling for OTC products as a means of addressing
toxicity concerns, serious drug interactions, fears about delaying medical
intervention, and so forth.37
In some situations, labeling may attempt to dictate prescription-only
use in a subclass of consumers.  For instance, most ingested OTC products
must include a warning that pregnant or nursing women should “seek the
advice of a health professional before using this product.”38  Conversely,
when it switched the oxybutynin patch for overactive bladder (Oxytrol®)
OTC, the FDA did so only for women because physicians first would need
bution restrictions); Lars Noah, Medicine’s Epistemology: Mapping the Haphazard Dif-
fusion of Knowledge in the Biomedical Community, 44 ARIZ. L. REV. 373, 456 (2002)
(“[P]hysicians may tune out if overwhelmed with risk information.”); cf. id. at 442
(“[T]he agency’s optimistic assumption [expressed in the course of proposing a
rule in 2000] that most physicians rely to some extent on the package insert seems
naive.”); Noah, supra note 2, at 64 (“[T]he agency may have placed excessive faith
in the good sense of physicians and the power of labeling to encourage proper use
and to limit the occasions for inappropriate prescribing.”).
35. 21 C.F.R. § 330.10(a)(4)(v) (2018).  Almost two decades ago, the agency
issued uniform formatting rules designed to improve the readability of OTC drug
labels. See Over-the-Counter Human Drugs; Labeling Requirements, 64 Fed. Reg.
13,254, 13,286 (Mar. 17, 1999) (codified at 21 C.F.R. § 201.66).
36. See Warner-Lambert/Parke-Davis & Co.: Benylin, 44 Fed. Reg. 51,512,
51,525 (Aug. 31, 1979) (“Suitable labeling of an OTC drug may provide sufficient
safeguards for a drug that presents such indirect risks [from drowsiness].  When a
drug presents serious direct risks (e.g., of cancer or other serious disease), ade-
quate labeling for lay use without medical supervision generally cannot be
written.”).
37. See Noah, The Imperative to Warn, supra note 34, at 320–26; id. at 320 (“Be-
cause few drugs are entirely risk free, OTC drug products can be marketed only if
consumers are given information adequate to minimize the danger of any side
effects.”); id. at 322 (“These ‘Warnings’ are action-oriented directives intended to
ensure safe product use rather than mere disclosures of risk information.”); id. at
326 (“Because OTC products are intended for self-treatment, the [FDA’s] empha-
sis on instructional warnings rather than [chronic] risk disclosures seems entirely
appropriate.”); see also infra Parts II.B & III (discussing the FDA’s tendency to use
labeling revisions as a means to deal with newly discovered risk information).
38. Amendment of Labeling Requirements for Over-the-Counter Human
Drugs, 47 Fed. Reg. 54,750, 54,757–58 (Dec. 3, 1982) (codified as amended at 21
C.F.R. § 201.63(a)) (applicable to all OTC drugs intended for systemic absorp-
tion); see also id. at 54,755 (responding to a comment that viewed this proposal as
antithetical to OTC status).
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to rule out prostate cancer as a possible cause of this condition in men.39
In switching a lower-dose version of the weight-loss drug Xenical® (orlis-
tat) to OTC status (sold as Alli®), the agency demanded labeling that spec-
ified only adult use.40  When these sorts of recommendations appear in
nonprescription product labeling, however, they do not actually represent
prescription restrictions because consumers remain entirely free to disre-
gard such advice.41
B. Routes to the Nonprescription Marketplace
For drugs that do not require the supervision of a physician, have a
history of safe use, and present no abuse potential, the FDA has a pair of
ways to authorize OTC marketing.42  First, a company may sell a nonpre-
scription drug if it abides by the terms of the applicable “monograph,”
which specifies for a particular category of products the active ingredients
and dosages that the agency has determined to be “generally recognized”
as safe and effective (GRAS/E), along with the precise labeling necessary
to facilitate appropriate consumer use.43  Any continued prescription mar-
39. See FDA, Need Relief from Overactive Bladder Symptoms?, https://www.fda
.gov/ForConsumers/ConsumerUpdates/ucm426099.htm [https://perma.cc/
U5ZC-UTMG] (last visited Feb. 2, 2018).
40. See Diedtra Henderson, 1st Over-Counter Diet Pill Approved; Use Requires Other
Weight-Loss Steps, BOS. GLOBE, Feb. 8, 2007, at A1 (“[T]he FDA approved Alli for
sale only to those who are at least 18 years old.  The agency, however, stopped
short of restricting access to the drug through such measures as requiring that it
be placed behind a pharmacist’s counter or requiring proof of age at purchase.”);
cf. Julie P. Karpinski et al., Smoking Cessation Treatment for Adolescents, 15 J. PEDIATRIC
PHARMACOLOGY & THERAPEUTICS 249, 258 (2010) (“[W]hile the OTC purchase of
[nicotine replacement therapy] is not permitted by adolescents, adolescents may
obtain the products under the supervision of a physician via a prescription.”).
41. See Tummino v. Hamburg, 936 F. Supp. 2d 162, 173 (E.D.N.Y. 2013) (ob-
serving that “a diet drug, Alli, ‘was approved [OTC] for weight loss in 2007 only for
adults 18 and older,’ although it could be purchased by teenagers”); id. at 180
(noting “[t]he FDA’s willingness to rely on labeling to make these drugs available
for sale over-the-counter without any age or point-of-sale restrictions, even though
they are unsafe for unsupervised use by young adolescents”); id. at 184 (same).
42. See Parke-Davis & Co. v. Califano, 564 F.2d 1200, 1201–03 (6th Cir. 1977);
Stan Stringer, What Has Been Happening with Over-the-Counter Drug Regulation, 53
FOOD & DRUG L.J. 633, 635 (1998).  Anyone may initiate an effort to exempt a
product from prescription status. See 21 C.F.R. § 310.200(b) (2018).  Although an
interested party presumably could try to use comparable procedures for going in
the opposite direction, no parallel rule so specifies.
43. See 21 C.F.R. § 330.1 (2018); see also Cutler v. Hayes, 818 F.2d 879, 883–85
(D.C. Cir. 1987) (describing the OTC drug review process); Kenneth C. Baumgart-
ner, A Historical Examination of the FDA’s Review of the Safety and Effectiveness of Over-
the-Counter Drugs, 43 FOOD DRUG COSM. L.J. 463 (1988) (offering an exhaustive
review of the first decade and a half).  After the agency issues a final monograph,
marketing of an OTC product outside of its scope would require favorable FDA
action on either a petition to amend the monograph or an application for new
drug approval. See Robert G. Pinco & Michael W. Cogan, Prescription to Over-the-
Counter Switches: An Example of the Need for New Procedures in the Post-Monograph Era,
39 FOOD DRUG COSM. L.J. 230, 235–38 (1984).
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keting of active ingredients for indications recognized in an OTC mono-
graph would constitute a misbranding violation under the FDCA.44
Conversely, nonmonograph ingredients, dosages, and indications could
only be marketed under an approved new drug application (NDA).45  The
FDA has used the monograph process as a mechanism for switching doz-
ens of drugs formerly limited to prescription-only use.46
The second route to OTC marketing requires that a company file a
supplement to an approved NDA or a separate NDA for a reformulation
(including revised labeling and perhaps reduced dosage) of a product
44. See 21 C.F.R. § 310.200(d); see also 21 U.S.C. § 353(b)(4)(B) (2012) (pro-
viding that a drug exempted from prescription requirements would be mis-
branded if it used the prescription warning statement or otherwise suggested that
it is for prescription use); Cough, Cold, Allergy, Bronchodilator, and An-
tiasthmatic Drug Products for Over-the-Counter Human Use; Tentative Final Mon-
ograph for Combination Drug Products, 53 Fed. Reg. 30,522, 30,527 (Aug. 12,
1988) (to be codified at 21 C.F.R. pt. 341) (“[A]fter the effective date of the final
OTC drug monograph (usually 12 months after its publication in the Federal Regis-
ter), if the ingredient and indication are included in the monograph, a drug prod-
uct containing the ingredient as switched to OTC status may not be marketed as a
prescription product.”).
45. See NRDC v. FDA, 710 F.3d 71, 75 (2d Cir. 2013) (“Like a recipe, each
monograph sets out the FDA-approved active ingredients for a given therapeutic
class of OTC drugs and provides the conditions under which each active ingredi-
ent is GRAS/E. . . .  Manufacturers desiring to market OTC drugs that are ex-
cluded from the monograph may not do so without obtaining individualized FDA
approval.”).  If an active ingredient got excluded for failing to satisfy the criteria
for allowing OTC sale (and, hence, would “misbrand” an OTC product containing
such an ingredient), then the NDA would have to propose use of prescription
labeling.  If, instead, an ingredient got excluded from a monograph based on a
judgment that it lacked general recognition of safety or effectiveness, then a spon-
sor willing to undertake clinical trials to produce such evidence could file an NDA
seeking approval as an OTC drug. See Rachanow, supra note 29, at 208 (explaining
that this had happened with the sleep-aid doxylamine succinate); see also United
States v. Articles of Drug . . . Promise Toothpaste, 826 F.2d 564, 569-73 (7th Cir.
1987) (holding that the manufacturer of a combination product for dental sensi-
tivity should have done so because it fell outside of the terms of the pending OTC
monograph).
46. See Fisher, supra note 30, at 612; id. at 627 (“[T]he OTC Drug Review
greatly accelerated the prescription-to-nonprescription switch movement, reflect-
ing the conclusions of experts that at least forty theretofore prescription ingredi-
ents are safe and effective for use by consumers on a nonprescription basis.”); see
also Marketing Status of Ingredients Recommended for Over-the-Counter Use, 41
Fed. Reg. 32,580, 32,581–82 (Aug. 4, 1976) (codified at 21 C.F.R. § 330.13) (invit-
ing use of the OTC drug review to switch prescription products).  Occasionally, the
FDA has accomplished what amounts to an OTC switch from a different baseline—
namely, prohibiting sale of a product as a dietary supplement or food but allowing
sale as a nonprescription drug. See Final Rule Declaring Dietary Supplements Con-
taining Ephedrine Alkaloids Adulterated Because They Present an Unreasonable
Risk, 69 Fed. Reg. 6788, 6793 (Feb. 11, 2004) (codified at 21 C.F.R. pt. 119); Pro-
posed Rule, Saccharin and Its Salts, 42 Fed. Reg. 19,996, 20,004 (Apr. 15, 1977) (to
be codified in scattered parts of 21 C.F.R.); cf. Nat’l Nutritional Foods Ass’n v.
Mathews, 557 F.2d 325, 334–36 (2d Cir. 1977) (invalidating rules that treated high-
dose vitamin A and D products as prescription drugs).
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previously approved for prescription use.47  Manufacturers generally initi-
ate switches of drugs that remain subject to NDAs, though they sometimes
fail to persuade the FDA to take this action.48  The agency may require
that the applicant conduct so-called actual use and label comprehension
studies.49  Dual marketing of an active ingredient for both a prescription
and OTC use is possible under limited circumstances.50  For instance, the
agency has approved ibuprofen (e.g., Motrin®) at different dosages as a
prescription and an OTC analgesic.51  In the event of reduced dosage for-
47. See 21 C.F.R. § 330.11; id. § 310.201(a) (listing these previously approved
active ingredients); Public Hearing, Over-the-Counter Drug Products, 65 Fed. Reg.
24,704, 24,704–05 (Apr. 27, 2000).  In some cases, after several years of OTC mar-
keting under the terms of an NDA, the FDA may propose including an ingredient
in the relevant monograph, which would allow other companies to sell it without
having to secure a separate license to do so. See, e.g., Sunscreen Drug Products for
Over-the-Counter Human Use, Amendment to the Tentative Final Monograph, 61
Fed. Reg. 48,645 (Sept. 16, 1996) (to be codified at 21 C.F.R. pt. 352).
48. See, e.g., United States v. An Undetermined Quantity . . . Benylin Cough
Syrup, 583 F.2d 942, 944–46 (7th Cir. 1978); Andrew Pollack, Pfizer Is Said to Want
New Lipitor Drug, N.Y. TIMES, Aug. 4, 2011, at B4 (“Merck failed three times to win
the agency’s approval for over-the-counter versions of Mevacor . . . .  Bristol-Myers
Squibb also failed to obtain approval for an over-the-counter version of Pravachol,
another [cholesterol-lowering] statin.”).
49. See, e.g., Tummino v. Hamburg, 936 F. Supp. 2d 162, 171–79, 189–91
(E.D.N.Y. 2013) (discussing at length the label comprehension and actual use stud-
ies submitted in support of switching emergency contraceptive products); see also
Brass, supra note 11, at 811–12, 814; R. William Soller, The Over-the-Counter Scien-
tific/Regulatory Paradigm, 33 DRUG INFO. J. 799, 801–02 (1999).
50. See Drug Approvals: Circumstances Under Which an Active Ingredient
May Be Simultaneously Marketed in Both a Prescription Drug Product and an
Over-the-Counter Drug Product, 70 Fed. Reg. 52,050, 52,051 (Sept. 1, 2005) (offer-
ing a half dozen examples where “some meaningful difference exists” between two
approved versions of products containing the same active ingredient).  After ini-
tially refusing to switch an emergency contraceptive (the so-called “morning after
pill”), the FDA viewed dual marketing as a compromise, wanting to require a pre-
scription below a certain age, which it kept shifting, even though the drug had an
unimpeachable safety profile.  Its foot-dragging attracted tremendous controversy,
and it took a court order to force the agency’s hand and allow full OTC availability.
See Tummino, 936 F. Supp. 2d at 166, 197–98, denial of stay pending appeal, 936 F.
Supp. 2d 198, 209 (E.D.N.Y. 2013); id. at 200 (“The effort to convert these levo-
norgestrel-based contraceptives from prescription to over-the-counter status has
gone on for over twelve years, even though they would be among the safest drugs
available to children and adults on any drugstore shelf.”); see also Michael D. Shear
& Pam Belluck, Obama to Drop Limit on Selling a Contraceptive, N.Y. TIMES, June 11,
2013, at A1 (reporting that the government decided against appealing the deci-
sion). See generally Lisa Heinzerling, The FDA’s Plan B Fiasco: Lessons for Administra-
tive Law, 102 GEO. L.J. 927 (2014).
51. See Linda M. Katz, Prescription to Over-the-Counter Drug Switches, 48 FOOD &
DRUG L.J. 567, 567 (1993) (differentiating such dual status products from “a com-
plete switch”); see also Stephanie Saul, F.D.A. Approves an Over-the-Counter Version of
the Weight-Loss Drug Xenical, N.Y. TIMES, Feb. 8, 2007, at A16.  Even less frequently,
the FDA has permitted continued prescription marketing of a drug for some uses
(e.g., gastrointestinal reflux disease) while it switched the same strength product
OTC when labeled for other uses (e.g., heartburn). See Alex Berenson, Where Has
All the Prilosec Gone?, N.Y. TIMES, Mar. 2, 2005, at C1.
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mulations, it did not take long for consumers to realize that they could
self-medicate with a prescription strength simply by exceeding the dose
recommended in the labeling.52
By all accounts, the OTC monograph process has gotten bogged
down.  Decades have passed with some major categories still unfinished.53
In 2014, for instance, frustrated that it took the FDA more than thirty
years to finalize most of the monograph for products intended to protect
against sun exposure, Congress unanimously passed legislation designed
to expedite the continuing review as well as to facilitate the approval of
novel ingredients.54  Conversely, and in contrast to the greater ease of call-
ing for revisions in the labeling of products switched through the NDA
mechanism, the agency has expressed frustration about its inability to re-
spond to new data because it would have to initiate rulemaking to amend
a monograph.55  Congress may soon take action on this broader front,56
52. See Brass, supra note 11, at 812, 814; Emilie le Beau, A Dose of Caution:
Whether You’re Big or Small, Don’t Self-Correct Drug Amounts, CHI. TRIB., Dec. 18, 2005,
at Q9 (“Forty-eight percent of people admitted to taking more than the recom-
mended dose of an OTC drug, believing it would make the drug more effective,
according to a recent survey by the National Council on Patient Information and
Education.”); see also Bober v. Glaxo Wellcome PLC, 246 F.3d 934, 939–40, 942
(7th Cir. 2001) (rejecting a state law consumer fraud claim against the manufac-
turer of Zantac® (ranitidine) for suggesting that two doses of the 75 mg OTC ver-
sion could not be substituted for the prescribed 150 mg version); Lance W. Rook,
Listening to Zantac: The Role of Non-Prescription Drugs in Health Care Reform and the
Federal Tax System, 62 TENN. L. REV. 107, 119 n.65 (1994) (“The drug manufac-
turer’s ability to claim that its OTC product used to be available only by prescrip-
tion appears to be a big marketing advantage.  This is, presumably, because drugs
that were once available only by prescription are viewed as more potent than non-
switched OTC medications.”).
53. See Peter Barton Hutt, The State of Science at the Food and Drug Administra-
tion, 60 ADMIN. L. REV. 431, 447–48 & n.71 (2008); see also NRDC v. FDA, 710 F.3d
71, 75–76, 80–-83 (2d Cir. 2013) (allowing a public interest group, which alleged
that triclosan used in antibacterial soaps may act as an endocrine disruptor and
endanger health, to challenge the agency’s delay in finalizing the OTC mono-
graph for topical antiseptics after it had proposed 35 years earlier to exclude this
ingredient).
54. See Sunscreen Innovation Act, Pub. L. No. 113–195, § 2, 128 Stat. 2035,
2035–45 (2014) (codified at 21 U.S.C. §§ 360fff to 360fff-5); Brady Dennis, The
Biggest Impasse Under the Sun, DENV. POST, May 18, 2015, at 1C.  This legislation
included provisions designed to speed the review of non-sunscreen ingredients as
well. See Proposed Rule, FDA Review and Action on Over-the-Counter Time and
Extent Applications, 81 Fed. Reg. 19,069, 19,072, 19,084–86 (Apr. 4, 2016) (to be
codified at 21 C.F.R. §§ 330.14–.15).
55. See Public Hearing, Over-the-Counter Drug Monograph System—Past,
Present, and Future, 79 Fed. Reg. 10,168, 10,170 (Feb. 24, 2014); see also id. (con-
ceding that many monographs have not yet gotten finalized, and, for these and
other reasons, seeking public comments about the continued viability of this
mechanism).
56. See Elyse Stoltz Dickerson, Opinion, Over-the-Counter Medicines Deserve Better
Treatment, FT. WORTH STAR-TELEGRAM (Tex.), Sept. 27, 2017; Malcolm Spicer, OTC
Monograph Reform Momentum Carries Potential Exclusivity Snag, ROSE SHEET, Jan. 18,
2018, available in Lexis News library.
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making it a good time to highlight a different set of questions that no one
seems to be terribly interested in confronting—namely, when and how
should the FDA revisit the fundamental judgment about a product’s suita-
bility for OTC marketing?
II. NONNARCOTIC PAINKILLERS OFFER A CAUTIONARY TALE
Because analgesics relieve symptoms and do not purport to treat any
underlying disease process, they would seem to represent natural candi-
dates for OTC marketing.57  Nonetheless, even if most consumers would
not need a physician’s diagnostic skills in order to decide whether to select
a particular pain reliever, and putting to one side narcotic analgesics that
raise concerns about abuse and diversion, the safety profile of such prod-
ucts may justify restrictions on access.  Thus, the FDA requires prescription
labeling when it first approves a new analgesic product, and many of these
drugs never get switched OTC.58  After they do manage to leave prescrip-
tion status, however, no amount of evidence of newly discovered hazards
seems enough to warrant switching them back; instead, time and again,
the agency prefers to add still more information to the labels of these
drugs.
A. Transitioning Analgesics to Unsupervised Availability
The OTC drug review for internal analgesics commenced with a call
for data in 1972.59  Five years later, the advisory panel, which had consid-
ered forty-nine active ingredients, issued its recommendations.60  More
57. See Noah, supra note 2, at 57.  On the flimsiness, however, of the distinc-
tion between symptoms and disease, see Lars Noah, Pigeonholing Illness: Medical Di-
agnosis as a Legal Construct, 50 HASTINGS L.J. 241, 262-63 (1999).
58. See Noah, supra note 2, at 56–58.  After all, COX-2 inhibitors (e.g., Vioxx®)
looked like potential switch candidates because they claimed to avoid a side effect
associated with OTC analgesics (and were costing insurers a mint), see Dennis
Cauchon, “Complex Issues” Require Much Study Before Action, FDA Says: Administra-
tion’s Decision on Allergy Drugs Could Have Wide Repercussions, USA TODAY, Apr. 12,
2000, at 5A, but the belated discovery of cardiac risks put an end to any such possi-
bility, see Alex Berenson et al., Despite Warnings, Drug Giant Took Long Path to Vioxx
Recall, N.Y. TIMES, Nov, 14, 2004, § 1, at 1.  Newer research suggests, however, that
the sole remaining COX-2 inhibitor poses no greater cardiovascular hazards than
analgesic products available OTC. See Gina Kolata, Celebrex Is Found to Be No Riskier
for Hearts Than Other Pain Drugs, N.Y. TIMES, Nov. 14, 2016, at A20.
59. See Over-the-Counter Internal Analgesic and Antirheumatic Drug Prod-
ucts, Safety and Efficacy Review, Request for Data and Information, 37 Fed. Reg.
14,633 (July 21, 1972).  The review included the use of such products for reducing
inflammation and fever as well as for relieving pain.
60. See Establishment of a Monograph for OTC Internal Analgesic, Antipy-
retic and Antirheumatic Products, 42 Fed. Reg. 35,346, 35,350, 35,422–34 (July 8,
1977) (to be codified at 21 C.F.R. pt. 343) (concluding, for instance, that a few
ingredients used in then-marketed analgesics (e.g., phenacetin) were not GRAS/
E); see also Baumgartner, supra note 43, at 484 (“Two leading OTC pain reliever
products, in advance of the publication of the TFM, removed ingredients, includ-
ing the ingredient phenacetin, not shown to be GRAS/E.”).
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than a decade later, the FDA published a tentative final monograph
(TFM) for this OTC drug category.61  In brief, this proposed rule included
aspirin and acetaminophen as permitted active ingredients and allowed
labeling “[f]or the temporary relief of minor aches and pains” with direc-
tions against taking analgesic products for more than ten days, accompa-
nied by an assortment of warning statements.62  In addition, during the
pendency of this OTC drug review, the FDA promulgated a requirement
that any nonprescription products containing aspirin include a special
warning against use during pregnancy.63  More than forty years after the
advisory panel completed its work, however, the monograph for internal
analgesics remains unfinished.64
Apart from this still-pending monograph process, some sponsors of
analgesics approved for prescription-only sale filed supplemental NDAs re-
questing OTC status.  In 1960, a dozen years before starting on the mono-
graph, the FDA authorized nonprescription marketing of lower doses of
acetaminophen (e.g., Tylenol®).65  A quarter of a century later, the agency
approved OTC sale of a lower dose product containing ibuprofen, a non-
steroidal anti-inflammatory drug (NSAID).66  Thereafter it switched sev-
eral other NSAIDs, including naproxen (e.g., Aleve®) and ketoprofen
61. See Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for
Over-the-Counter Human Use, Tentative Final Monograph, 53 Fed. Reg. 46,204
(Nov. 16, 1988) (to be codified at 21 C.F.R. pts. 310, 343, 369).
62. See id. at 46,255–56.  The TFM includes a number of warnings applicable
to aspirin. See id. at 46,256 (to be codified at 21 C.F.R. § 343.50(c)).
63. See Labeling for Oral and Rectal Over-the-Counter Aspirin and Aspirin-
Containing Products; Final Rule, 55 Fed. Reg. 27,776, 27,784 (July 5, 1990) (codi-
fied at 21 C.F.R. § 201.63(e)); see also Martha M. Werler et al., Use of Over-the-Counter
Medications During Pregnancy, 193 AM. J. OBSTETRICS & GYNECOLOGY 771, 776 (2005)
(finding that use of aspirin by pregnant women has decreased while their use of
other OTC drugs has increased); id. at 777 (“The common use of OTC medicines
in pregnancy necessitates further studies to establish safety or to identify risks.”).
64. The latest unified regulatory agenda shows this and several other
monographs under the “long-term actions” heading. See Regulatory Agenda, 83
Fed. Reg. 1860, 1861, 1864-65 (Jan. 12, 2018).
65. See Natasha Singer, Robert L. McNeil Jr., 94; Introduced Tylenol Brand, N.Y.
TIMES, June 4, 2010, at A25 (“Approved by the [FDA], Tylenol went on the market
as a prescription medication in 1955. It became an over-the-counter drug in
1960.”).  The agency actually had exempted acetaminophen from prescription dis-
pensing requirements a few years earlier. See Republication of Regulations, 20 Fed.
Reg. 9525, 9648 (Dec. 20, 1955) (codified as renumbered at 21 C.F.R.
§ 310.201(a)(1)).
66. See Irvin Molotsky, Agency Approves Painkiller for Over-the-Counter Sales, N.Y.
TIMES, May 19, 1984, § 1, at 1; see also supra note 51 and accompanying text (ex-
plaining that higher doses remained in prescription status).  Many years later, the
FDA proposed amending the TFM to add ibuprofen as a monograph ingredient.
See Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-
Counter Human Use; Proposed Amendment of the Tentative Final Monograph,
and Related Labeling, 67 Fed. Reg. 54,139, 54,158–59 (Aug. 21, 2002) (to be codi-
fied at 21 C.F.R. pts. 201, 343).
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(e.g., Orudis®), to nonprescription status.67  Consumers today can select
among a wide array of painkillers.
B. Accumulating and Communicating New Risk Information
OTC analgesics may pose significant risks,68 which the agency gener-
ally has tried to handle through revisions in labeling.  In addition to con-
cerns about kidney and liver damage, researchers have linked prolonged
use of NSAIDs to sometimes fatal gastrointestinal bleeding.69  Then, in the
early 1980s, the FDA became aware of a suspected link between Reye’s
syndrome and the use of aspirin by children suffering from viral infec-
tions.70  The labels of OTC drug products containing aspirin and related
ingredients now must include the following statement: “Children and
teenagers who have or are recovering from chicken pox or flu-like symp-
toms should not use this product.  When using this product, if changes in
behavior with nausea and vomiting occur, consult a doctor because these
symptoms could be an early sign of Reye’s syndrome, a rare but serious
illness.”71  Notably, when it originally mandated an earlier version of this
warning, the agency had rejected suggestions urging “more drastic mea-
sures [such as] banning use of aspirin in products for individuals under 21
years of age or limiting such products to prescription use.”72
67. See Gary Mays, Pain-Killer Wars Can Be a Pain for Ailing Consumers; Product
Proliferation Likely Will Continue as Firms Try to Provide Greater Flexibility, CHI. TRIB.,
Nov. 24, 1995, at B1.
68. See Boodman, supra note 10, at F1 (“Each year, . . . about 16,000 die from
complications related to the use of OTC painkillers. . . .  Some health officials say
that the actual number of injuries and deaths is considerably higher because many
cases go unrecognized or unreported, especially among the elderly, many of whom
take multiple medications.”); Mary Duenwald, Choosing a Pain Remedy Carefully, N.Y.
TIMES, July 6, 2004, at F5.
69. See Noah, supra note 2, at 65 nn.19–20, 67 n.52; Jane E. Brody, Finding
Better Ways to Manage Pain, N.Y. TIMES, Sept. 5, 2017, at D5 (“In addition to cardio-
vascular risks, NSAIDs can cause gastrointestinal problems, damaging the lining of
the digestive tract, especially when they are not taken with food.  Their most seri-
ous side effects include ulcers, bleeding, kidney failure and, in rare cases, liver
failure.”).
70. See Proposed Labeling for Oral Aspirin-Containing Drug Products, 50
Fed. Reg. 51,400, 51,401 (Dec. 17, 1985); see also Pub. Citizen Health Research
Group v. Comm’r, FDA, 740 F.2d 21, 34–35 (D.C. Cir. 1984) (remanding for lower
court to consider a claim of unreasonable delay by the FDA in acting on a citizen
petition urging it to require a warning of this risk); Am. Home Prods. Corp. v.
Johnson & Johnson, 672 F. Supp. 135, 137–41 (S.D.N.Y. 1987) (offering a detailed
account of the history behind the early Reye’s syndrome warning efforts).
71. 21 C.F.R. § 201.314(h)(1) (2018).
72. Labeling for Oral and Rectal Over-the-Counter Aspirin and Aspirin-Con-
taining Drug Products; Reye Syndrome Warning, 53 Fed. Reg. 21,633, 21,635
(June 9, 1988); see also United States v. Article of Drug . . . “Decholin,” 264 F. Supp.
473, 482 n.9 (E.D. Mich. 1967) (noting that the FDA would not limit aspirin to
prescription use even though “at the root of a headache may lie anything from
nervous tension to a malignant brain tumor”); cf. Harvey J. Weiss, Aspirin: A Danger-
ous Drug?, 229 JAMA 1221 (1974) (suggesting prescription-only status).  In con-
trast, with mounting reports of emergency room visits for young children using
15
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More recently, after it received reports of an association between
acetaminophen and liver toxicity, the FDA imposed special warning re-
quirements.73  Even in the absence of alcohol consumption, reports of
liver toxicity from accidental overdoses have increased with the expanding
use of acetaminophen in combination prescription as well as nonprescrip-
tion drug products.74  Hence, acetaminophen exhibits a narrow margin of
safety,75 which typically makes an ingredient ineligible for OTC
availability.76
In addition, the FDA has called for warnings that acetaminophen may
cause the sometimes fatal skin conditions Stevens-Johnson Syndrome and
toxic epidermal necrolysis,77 which NSAIDs already had to disclose.78  The
OTC cough-cold remedies, the industry opted to add an age limitation (four-year-
olds and older) in product labeling. See Gardiner Harris, Cold Drugs for Children
Will Carry New Warning, N.Y. TIMES, Oct. 8, 2008, at A17 (adding that the compa-
nies previously had stopped marketing these products for use in children under
two-years of age); see also Matthew Perrone, FDA Warns Teething Medicines Unsafe,
Wants Them off Shelves, ST. LOUIS POST-DISPATCH, May 24, 2018, at A1 (“[V]arious
gels and creams containing the drug benzocaine can cause rare but deadly side
effects in children, especially those 2 years and younger. The agency has been
warning about the products for a decade but said reports of illnesses and deaths
have continued . . . [and] there is little evidence they actually work.”).  As ex-
plained earlier, however, such age restrictions—in this case directed to parents
and guardians—function only as advisories. See supra notes 40–41 and accompany-
ing text.
73. See Over-the-Counter Drug Products Containing Analgesic/Antipyretic
Active Ingredients for Internal Use; Required Alcohol Warning, 63 Fed. Reg.
56,789, 56,801–02 (Oct. 23, 1998) (codified at 21 C.F.R. § 201.322) (warning
against the use of internal analgesics in combination with heavy alcohol consump-
tion); see also Benedi v. McNeil-P.P.C., Inc., 66 F.3d 1378, 1387, 1389 (4th Cir.
1995) (sustaining a negligence claim and punitive damage award against the seller
of Tylenol where it had delayed submitting adverse reaction reports—concerning
liver toxicity resulting from interactions between acetaminophen and alcohol—to
the FDA during the OTC drug review for internal analgesics).
74. See Deborah Franklin, Poisonings from a Popular Pain Reliever Are on the Rise,
N.Y. TIMES, Nov. 29, 2005, at F5; Matthew Perrone, Tylenol, Implicated in Liver Fail-
ure, Will Carry New Warning, BOS. GLOBE, Aug. 30, 2013, at B7 (“Overdoses from
acetaminophen send 55,000 to 80,000 people to the emergency room in the
United States each year and kill at least 500, according [to] the Centers for Disease
Control and Prevention and the [FDA].”); see also Melissa Dribben, Suits Against
Tylenol Maker Seek to Highlight Dangers, PHILA. INQUIRER, Feb. 16, 2014, at G1 (dis-
cussing criticism of the FDA’s slow and limited responses to this problem).
75. See Dribben, supra note 74, at G1 (“[I]t has a narrow margin of safety and
can quickly become toxic when taken in doses not much greater than the recom-
mended limits, or when combined with alcohol.”); Denise Gellene, Even at Advised
Doses, Tylenol May Harm Liver; Though Overdoses Have Been Linked to Organ Damage,
the Study Is the First to Suggest Trouble in Healthy People Taking the Drug as Directed, L.A.
TIMES, July 5, 2006, at A13.
76. See supra note 29 and accompanying text.
77. See Recommended Warning for Over-the-Counter Acetaminophen-Con-
taining Drug Products and Labeling Statements Regarding Serious Skin Reactions;
Guidance for Industry, 82 Fed. Reg. 3332, 3333 (Jan. 11, 2017).
78. See FDA Links Painkiller to Fatal Skin Conditions, WASH. POST, Aug. 2, 2013,
at A10 (“Other drugs used to treat fever and pain, such as ibuprofen and
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agency also has ordered stronger warnings about the increased risk of
heart attack and stroke associated with aspirin and NSAIDs such as
ibuprofen.79  Notwithstanding the growing litany of risk disclosures for
OTC analgesics, many consumers regularly exceed the recommended
doses or otherwise disregard information appearing in the labeling for
these drugs.80
III. ESCALATING CONCERNS ABOUT THE HAZARDS POSED
BY OTHER OTC DRUGS
The track record with internal analgesics hardly represents an outlier.
This Part catalogs newly discovered dangers associated with popular non-
prescription treatments for heartburn and allergies as well as hazards
linked to unexpected patterns of abuse with a pair of other products.  As it
did in the case of OTC pain relief products, the FDA typically responded
with calls for revised labeling.  Only once in recent memory has the agency
proposed rescinding nonprescription status for an ingredient that it previ-
ously (though only tentatively) had authorized for unsupervised use.
Because NSAIDs irritate the lining of the stomach, consumers often
take heartburn remedies to guard against this side effect, but doing so (or
taking them for other reasons) may bring a new set of problems.81  Proton
pump inhibitors, an effective new class of drugs for treating gastric dis-
tress,82 again illustrate what can happen after an Rx-to-OTC switch.  In
naproxen, also carry the risk of serious skin conditions, but the risk is already de-
scribed in the warning section of those drug labels, the FDA said.”).
79. See Sabrina Tavernise, F.D.A. Is Set to Toughen Nonaspirin Warnings, N.Y.
TIMES, July 10, 2015, at A20; see also Gary C. Curhan et al., Frequency of Analgesic Use
and Risk of Hypertension in Younger Women, 162 ARCHIVES INTERNAL MED. 2204,
2207–08 (2002) (finding that the use of NSAIDs and acetaminophen caused an
increase in blood pressure but that aspirin did not); Scott Hensley, Rethinking Over-
the-Counter Drugs: Finding on Aleve Underscores Dearth of Overall Research; Little Incentive
for Trials, WALL ST. J., Dec. 22, 2004, at D1 (reporting that naproxen “appeared to
increase by about 50% the risk of cardiovascular problems, such as strokes and
heart attack, in elderly patients taking the drug daily for several years”).  Indeed,
the finding on naproxen prompted the FDA to impose its toughest risk labeling
revision (i.e., a “black box” warning) for prescription versions, but it allowed con-
tinued marketing of OTC versions with nothing more than the addition of a sim-
ple warning statement. See Marc Kaufman, Another Pain Reliever Pulled; FDA Warns
of Risk in Entire Class of Anti-Inflammatories, WASH. POST, Apr. 8, 2005, at A1.
80. See Jane E. Brody, Perils of Pain Relief Often Hide in Tiny Type, N.Y. TIMES,
May 3, 2005, at F7 (“[F]ar too many people use [analgesics] carelessly, without
adequate attention to dosage and warnings about possible risks.”); Alan Mozes,
Opioids Aren’t America’s Only Painkiller Problem, CHI. TRIB., Feb. 7, 2018, at D6
(“Among those surveyed who take over-the-counter ibuprofen (Motrin, Advil), 15
percent admitted to exceeding daily maximum dosage . . . .”); see also supra note 52
(discussing consumers’ tendency to exceed the recommended individual doses of
OTC drugs).
81. See Joe Graedon & Teresa Graedon, Dangers of OTC Drugs Often Given Short
Shrift, BALT. SUN, Jan. 5, 2017, at C4.
82. Histamine H2 receptor antagonists (a.k.a. H2 blockers) represented an
earlier generation of heartburn drugs and witnessed several major Rx-to-OTC
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2003, after initially rejecting an application, the FDA allowed Prilosec®
(omeprazole) to leave prescription status for certain uses.83  Some critics
expressed concerns about this decision, pointing out that unsupervised
use might mask more serious underlying conditions that then would go
undiagnosed and untreated, but the agency viewed that possibility as re-
mote.84  Other proton pump inhibitors soon followed Prilosec into the
nonprescription marketplace, including Prevacid® (lansoprazole) and
Nexium® (esomeprazole).85
Before long, however, worrisome reports about these OTC drugs be-
gan to accumulate.86  First, researchers discovered that users became
more prone to a dangerous and difficult-to-treat type of intestinal infec-
tion.87  Second, proton pump inhibitors appeared to interact with certain
anticoagulants that rendered these critical prescription drugs less effec-
tive.88  Third, researchers found that long-term use of proton pump inhib-
switches (sold under brand-names such as Pepcid®, Tagamet® and Zantac®). See
Davina C. Ling et al., Deregulating Direct-to-Consumer Marketing of Prescription Drugs:
Effects on Prescription and Over-the-Counter Product Sales, 45 J.L. & ECON. 691, 693–96,
703, 705–06 (2002).  The FDA handled drug interaction concerns through disclo-
sures in their labeling. See Francesca Lunzer Kritz, The Prescription-to-Nonprescription
Switch; Drug Agency Weighs Change of Status for Several Medicines, WASH. POST, July 25,
1995, at Z7 (“[T]he asthma drug theophylline; warfarin, a blood thinner; or
phenytoin, a drug to treat epilepsy . . . leave the body much more slowly when
mixed with Tagamet and can result in extremely rare instances in a buildup that
could cause convulsions and coma.”).
83. See Gardiner Harris, F.D.A. Approves Over-Counter Sales of Top Ulcer Drug,
N.Y. TIMES, June 21, 2003, at A1 (reporting that earlier efforts to switch Prilosec
had faltered).
84. See Hope Cristol, Heartburn of Another Kind: For Some Patients, Self-Treating
with New OTC Drugs May Invite Trouble, WASH. POST, Sept. 30, 2003, at F1 (“While
Prilosec labeling warns heartburn sufferers to see a doctor if symptoms persist after
14 days, it does not address the risk of cancer or Barrett’s esophagus.”); see also
Shari Roan, When Antacids Aren’t Enough; That Chronic Heartburn Could Be a Sign of
Something More Serious; Doctors Are Seeing More Cases of Rare but Deadly Esophageal Can-
cer, L.A. TIMES, Apr. 10, 2006, at F1.
85. See Nicholas Bakalar, Drug: Heartburn Drugs and Mortality, N.Y. TIMES, July
11, 2017, at D4.  The OTC drug Zegrid® combines the active ingredient in Prilosec
with sodium bicarbonate.  At present, other proton pump inhibitors, including
AcipHex® (rabeprazole), Dexilant® (dexlansoprazole), and Protonix® (panto-
prazole), remain Rx-only.
86. See Adam J. Schoenfeld & Deborah Grady, Editorial, Adverse Effects Associ-
ated with Proton Pump Inhibitors, 176 JAMA INTERNAL MED. 172, 172–74 (2016) (sum-
marizing newly discovered hazards); Dennis Thompson, Heartburn Meds May
Increase Risk of Death; Study Warns of Prolonged Use of Drugs, CHI. TRIB., July 19, 2017,
at D6.
87. See Sandra Dial et al., Use of Gastric Acid-Suppressive Agents and the Risk of
Community-Acquired Clostridium difficile-Associated Disease, 294 JAMA 2989, 2992
(2005) (focusing on prescription versions of these drugs); Seema Yasmin, Heart-
burn Meds May Trigger Gut Infection, SAN DIEGO UNION TRIB., May 9, 2017, at E1.
88. See Alicia Mundy, FDA Underscores Plavix Warning, WALL ST. J., Oct. 20,
2010, at D2 (“Federal regulators said they plan to reiterate a warning that patients
taking the anticlotting drug Plavix should avoid also taking the heartburn drug
Prilosec . . . .”); id. (explaining that a black box warning was added to the labeling
for this prescription anticoagulant to highlight the suspected interaction).
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itors was associated with seizures,89 fractures,90 dementia,91 heart
attacks,92 stroke,93 liver disease,94 and kidney problems.95  Putting aside
uncertainties about a causal connection or the frequency of such effects,
though the agency took many of these seriously enough to communicate
new risk information,96 it seems entirely implausible to think that the FDA
would have authorized Rx-to-OTC switches in light of such concerns.97
Nonetheless, because these questions came to light only after the fact, the
agency so far has shown no indications that it might force previously
switched proton pump inhibitors back into prescription-only status.
Older antihistamines such as diphenhydramine (sold under brand-
names such as Benadryl®) have long included warnings that they may
cause sedation.  Indeed, some have become more popular as sleep aids
89. See Kay Lazar, Acid Reflux in Flux; The FDA Warns That Long-Term Use of
Proton Pump Inhibitors Could Have Adverse Effects, So Doctors Are Reevaluating the Popu-
lar Medication, BOS. GLOBE, Apr. 4, 2011, at G12 (reporting that the agency warned
that regular users “may end up with low magnesium levels, which can put them at
risk for seizures, irregular heartbeats, and muscle spasms”).
90. See id. (“Last May, the FDA said the drugs, both sold as prescriptions and
over-the-counter, may increase the risk of hip, wrist, and spine fractures, especially
for patients who are over 50 and have been taking them for longer than one year
or are receiving high doses.”).
91. See Nicholas Bakalar, Behavior: P.P.I.s Tied to Dementia, N.Y. TIMES, Feb. 23,
2016, at D6; see also Catherine Saint Louis, Study Links Long-Term Use of Acid-Sup-
pressing Drugs to Vitamin B12 Deficiency, N.Y. TIMES, Dec. 11, 2013, at A17.
92. See Lenny Bernstein, Heartburn Drugs Linked to Higher Heart Attack Risk,
WASH. POST, June 11, 2015, at A1.
93. See Dennis Thompson, Do Common Heartburn Drugs up Risk of Stroke?, CHI.
TRIB., Dec. 7, 2016, at D4.
94. See Bradley J. Fikes, Stomach Acid Blockers Promote Liver Disease, SAN DIEGO
UNION TRIB., Oct. 11, 2017, at A1.
95. See Lenny Bernstein, Popular Heartburn Pills Linked to Kidney Disease, WASH.
POST, Jan. 12, 2016, at A3.
96. See Lazar, supra note 89, at G12; Paula Span, Heartburn Solutions, and
Problems, N.Y. TIMES, Feb. 2, 2016, at D5 (“The [FDA] has also issued several safety
announcements about these drugs’ association with C. diff, fracture risk and low
magnesium, linked to kidney disease and other ailments.”).
97. Cf. Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Combina-
tion Drug Products Containing Promethazine Hydrochloride Marketing Status, 54
Fed. Reg. 36,762, 36,764 (Sept. 5, 1989) (deferring to an advisory committee rec-
ommendation against the agency’s proposal to allow OTC marketing of the anti-
histamine promethazine hydrochloride until it could resolve safety questions such
as the risk of sudden infant death syndrome); Rob Stein, Nonprescription Sales of
Cholesterol Drug Rejected: FDA Panel Says Risk of Side Effects Outweighs Benefits, WASH.
POST, Jan. 15, 2005, at A3 (“[T]he advisers were concerned that pregnant women
might take the drug [Mevacor®], resulting in birth defects, and that patients might
suffer rare but potentially life-threatening liver and muscle complications. . . .  FDA
officials said the company’s own research showed that consumers frequently mis-
understood who should take the drug . . . .”); F.D.A. Reviews Nonprescription Claritin,
N.Y. TIMES, Apr. 30, 2002, at C12 (reporting that, before switching loratadine, the
FDA looked into reports of a cluster of birth defects in Sweden that arose one
decade after original approval).  In other words, if the FDA knew back then what
we know now about these products, then it would never have permitted OTC
status.
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(sold under brand-names such as Unisom®) for this very reason.  Nonethe-
less, concerns about daytime sleepiness in users of these OTC antihista-
mines continue as have urgent calls for enhanced warnings.98  In the early
1990s, after studies had linked another sedating antihistamine (doxy-
lamine succinate) to the development of liver and thyroid tumors in ro-
dents, the FDA flirted with the idea of requiring a disclosure of this
information in product labeling.99  More recently, researchers have uncov-
ered an association between dementia and long-term use of the broader
class of anticholinergics, which includes diphenhydramine and doxy-
lamine among other OTC as well as prescription ingredients.100  Of
course, these and other hazards would not present a problem if consumers
conscientiously followed instructions on product labels calling only for
short-term use.101
Similarly, a potential for abuse, which normally would count against
an active ingredient’s eligibility for nonprescription access,102 may not be-
come evident until long after approval.  Such concerns prompted the FDA
to consider removing ipecac syrup from OTC status.  In 1965, it had au-
thorized marketing of this product, which induces vomiting, so long as
sold in small containers and labeled for use only as directed by a physician,
hospital, or poison control center.103  After reports of abuse by persons
with eating disorders such as bulimia (as well as by parents with Munchau-
sen syndrome), coupled with reasons to doubt that it actually helped in
cases of poisoning, the agency decided to revisit its decision: in 2003, it put
98. See Dennis Cauchon, Why Allergy Drugs Cost So Much, USA TODAY, Apr. 12,
2000, at 1A (“estimat[ing] that sedating antihistamines cause an average of about
600 auto fatalities per year”); Jeff Zeleny, NTSB Says Drugs Need More Label Warnings;
Drowsiness Cited as Contributing to Many Crashes, CHI. TRIB., Nov. 15, 2001, at A24.
99. See Noah, The Imperative to Warn, supra note 34, at 324–26 (discussing this
proposal, and explaining that the agency dropped the idea in 1994).
100. See Lisa Rapaport, Some Common Drugs May Cause Brain Changes, WASH.
POST, Apr. 26, 2016, at E3; see also Shelly L. Gray et al., Cumulative Use of Strong
Anticholinergics and Incident Dementia: A Prospective Cohort Study, 175 JAMA INTERNAL
MED. 401, 405–06 (2015) (focusing on prescription drugs from this broad class,
though noting that several first-generation antihistamines are available as OTC
medications); cf. Kathryn Richardson et al., Anticholinergic Drugs and Risk of Demen-
tia: Case-Control Study, 361 BMJ k1315 (2018) (exonerating antihistamines in this
class though implicating the incontinence drug oxybutynin).
101. Cf. Torsiello v. Whitehall Labs., 398 A.2d 132, 137–40 (N.J. App. Div.
1979) (holding that a jury could find the direction on Anacin® (aspirin and caf-
feine) to consult a physician if pain lasted for more than ten days was inadequate
to guard against the risk of gastrointestinal bleeding from prolonged use); Michael
v. Warner/Chilcott, 579 P.2d 183, 186–87 (N.M. Ct. App. 1978) (same, for an in-
struction on a decongestant containing phenacetin not to take the drug for more
than ten days without consulting a physician because it may cause kidney damage,
even though this language tracked a regulation that the FDA had promulgated in
1964).
102. See supra note 30 and accompanying text.
103. See Ipecac Syrup in One Fluid Ounce Containers; Required Warnings
and Directions, 30 Fed. Reg. 13,628 (Oct. 27, 1965) (codified as renumbered at 21
C.F.R. § 201.308).
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the question before one of its advisory committees,104 which voted to rec-
ommend against continued nonprescription availability.105  Perhaps rec-
ognizing that no seller then would have sought approval of a prescription-
only substitute,106 however, the agency failed to act on the advice that it
had received.107
In 2016, evidence emerged that the antidiarrheal agent loperamide
(sold under brand-names such as Imodium®) had unexpectedly become a
drug of abuse and caused serious injuries.108  The FDA responded first by
demanding that labels warn against ingesting such high doses, and then it
asked manufacturers to adopt more cumbersome blister packs for each
dose and include only enough doses for short-term use.109  Although evi-
dently not on the table as an option, the agency could switch loperamide
back to prescription-only use without much difficulty because, like a few
other OTC products,110 the ingredient remains separately approved as a
prescription drug at a higher dose; the FDA could simply withdraw its ap-
proval of the OTC version, which would leave legitimate consumers still
able to secure access through their physicians.
In rare cases, newly discovered risks with an OTC drug prompt more
drastic action than simply a call for additional information in labeling.
For example, the agency belatedly withdrew its tentative approval of
phenylpropanolamine (PPA), a nasal decongestant used in OTC cough-
104. See Nonprescription Drugs Advisory Committee; Notice of Meeting, 68
Fed. Reg. 24,004 (May 6, 2003).  Consumers with anorexia or bulimia also fre-
quently abuse OTC laxative products in ways that may endanger their health
wholly apart from the underlying eating disorder. See James L. Roerig et al., Laxa-
tive Abuse: Epidemiology, Diagnosis and Management, 70 DRUGS 1487, 1499 (2010).
105. See Elena Conis, Home Poison Aid Falls out of Favor; Ineffectiveness and Abuse
Lead the FDA to Reevaluate Ipecac, L.A. TIMES, July 28, 2003, at F5 (“The FDA’s non-
prescription drug advisory committee voted 6 to 4 last month in favor of revoking
ipecac’s over-the-counter status.  An FDA official said the agency was considering a
range of options for the syrup, . . . [including] a labeling change that would warn
users against taking ipecac for weight loss.”); see also Michael Shannon, The Demise
of Ipecac, 112 PEDIATRICS 1180, 1181 (2003).
106. See Jennifer Huget, Time to Purge the Ipecac?, WASH. POST, July 8, 2003, at
F1 (“It may take months or longer for the FDA to decide whether to strip ipecac of
its OTC status.  That change wouldn’t mean that ipecac would simply move to
prescription-only status; individual manufacturers would have to submit their prod-
ucts for FDA review . . . [, and] ipecac might not meet the FDA’s standards for
prescription drugs’ safety and efficacy.”).
107. After years of regularly forecasting that it would issue a notice of pro-
posed rulemaking (NPRM) within a matter of months, see, e.g., Unified Agenda, 70
Fed. Reg. 64,568, 64,575 (Oct. 31, 2005) (anticipating issuance of an NPRM by
June 2006), the FDA announced that it had dropped the idea, see Unified Agenda,
77 Fed. Reg. 7946, 7955 (Feb. 13, 2012) (indicating that it had “withdrawn” action
item no. 357 on Sept. 8, 2011).
108. See Catherine Saint Louis, Addicts Who Can’t Find Painkillers Turn to Anti-
Diarrhea Drugs, N.Y. TIMES, May 11, 2016, at A10.
109. See Laurie McGinley, FDA Looks to Curb Abuse of Anti-Diarrhea Drug Used as
Methadone Substitute, WASH. POST, Jan. 31, 2018, at A3.
110. See supra notes 50–52 and accompanying text (discussing dual status
products).
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cold and weight-loss products (sold under brand-names such as
Dimetapp® and Dexatrim®), after scientists confirmed a long-suspected as-
sociation with hemorrhagic stroke.111  After first proposing the addition of
a warning statement on nonprescription drugs while awaiting the results
of this study,112 the FDA issued a public health advisory in 2000 and a
proposed rule to withdraw PPA from the market altogether in 2005.113
The time that it took for the agency to take these steps,114 and the evi-
dence that it demanded before accepting the link between this nonessen-
tial ingredient and a grave though rare side effect, demonstrate once
again just how reticent the FDA has become about revisiting a decision to
allow nonprescription availability.115
111. See Jeff Gerth & Sheryl Gay Stolberg, Another Part of the Battle: Keeping a
Drug on the Shelves of Stores, N.Y. TIMES, Dec. 13, 2000, at A31 (reporting that the
FDA estimated 200–500 strokes annually); see also Walter N. Kernan et al., Phenyl-
propanolamine and the Risk of Hemorrhagic Stroke, 343 NEW ENG. J. MED. 1826,
1830–32 (2000); Glaser v. Thompson Med. Co., 32 F.3d 969 (6th Cir. 1994) (find-
ing sufficient evidence that the PPA in Dexatrim could have caused the plaintiff’s
stroke); In re Phenylpropanolamine (PPA) Prods. Liab. Litig., 289 F. Supp. 2d 1230
(W.D. Wash. 2003), further proceedings, 227 F.R.D. 553, 567–69 (W.D. Wash. 2004)
(approving $60 million class action settlement); Barbara J. Rothstein et al., A Model
Mass Tort: The PPA Experience, 54 DRAKE L. REV. 621, 635 (2006) (“The court [hear-
ing the multidistrict litigation] also found, however, that the scientific research did
not support expert testimony concerning the causal link between PPA and other
injuries [alleged by plaintiffs], including seizures, psychoses, cardiac injuries, and
any [stroke] injury occurring more than seventy-two hours after ingestion.”).
112. See Over-the-Counter Drug Products Containing Phenylpropanolamine;
Required Labeling, 61 Fed. Reg. 5912, 5915 (Feb. 14, 1996) (to be codified at 21
C.F.R. § 201.321), withdrawn, 73 Fed. Reg. 75,625 (Dec. 12, 2008) (explaining that
its subsequent proposal to withdraw PPA superseded this proposed warning
requirement).
113. See Phenylpropanolamine-Containing Drug Products for Over-the-
Counter Human Use; Tentative Final Monographs, 70 Fed. Reg. 75,988, 75,997
(Dec. 22, 2005) (to be codified at 21 C.F.R. § 310.545); id. at 75,994 (“In Novem-
ber 2000, FDA issued a public health advisory . . . .  [N]ational chain drugstore[s]
and major and smaller manufacturers voluntarily removed phenylpropanolamine-
containing OTC drug products from the market.”).  For another recent public
health advisory issued by the FDA, this one to alert consumers of OTC antiseptic
products of a small possibility of severe anaphylactic reactions, see FDA, Chlorhex-
idine Gluconate: Drug Safety Communication—Rare but Serious Allergic Reactions (Feb. 2,
2017), https://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsfor
humanmedicalproducts/ucm590808htm [https://perma.cc/4RY3-A35A] (last vis-
ited Feb. 2, 2018).
114. See Sarah Lueck, FDA Officials Suspected PPA Link to Higher Stroke Risk Since
’80s, WALL ST. J., Nov. 8, 2000, at B6.  Although the agency’s announcement
prompted remedial action by most manufacturers, the FDA still has not formally
ordered the withdrawal of this active ingredient; the latest unified regulatory
agenda shows final action on this proposal remains “To Be Determined” with re-
gard to PPA’s use in weight-loss products. See Regulatory Agenda, 83 Fed. Reg.
1860, 1865 (Jan. 12, 2018); cf. Regulatory Agenda, 76 Fed. Reg. 40,052, 40,066
(July 7, 2011) (indicating that it had withdrawn the proposal with regard to PPA’s
use in cough-cold products).
115. In two other instances, the FDA proposed an Rx-to-OTC switch but
backpedaled far more quickly in the face of strong objections voiced by health
professionals. See Noah, supra note 11, at 372–74 (discussing the bronchodilator
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During the OTC drug review process that had commenced in 1972,
the agency did remove several products from nonprescription status,116
but these involved ingredients that it had never before scrutinized.117
When the FDA excluded certain active ingredients from its monographs,
this happened because of an insufficient showing of effectiveness or per-
haps unresolved questions about safety when used without medical super-
vision.  In either case, sponsors would remain free to secure agency
approval of a nonprescription drug containing such ingredients so long as
they could produce adequate evidence of safety and effectiveness.118  In
metaproterenol (Alupent®) and exocrine pancreatic insufficiency products).  If
such objections had arisen only after the finalization of these monographs, how-
ever, the agency may not have bothered acting upon any such change of heart.
116. See Baumgartner, supra note 43, at 491 (“Final rules have also been is-
sued banning or removing from the market, principally for safety reasons, cam-
phorated oil, daytime sedatives, hexachlorophene, insect repellents (internal),
overindulgence (inebriation) remedies, salicylanilides, sweet spirits of nitre, and
zirconium (aerosol).” (footnotes omitted)); id. at 480 (“In another significant
safety measure not accomplished formally under the OTC drug review, the FDA in
1979 issued approximately 350 letters to drug manufacturers requesting that they
recall antihistamine drug products containing methapyrilene after it was deter-
mined that the ingredient was a potential carcinogen.”); Fisher, supra note 30, at
606 (“In the 1960s the FDA addressed several questions of toxicity, abuse, and
misuse of certain nonprescription drugs, including amyl nitrite inhalants, amphet-
amine and methamphetamine inhalers, and others, by placing them on prescrip-
tion.”); id. at 607 (adding that, during the OTC drug review, the agency
“remov[ed] from the market several nonnarcotic nonprescription drug ingredi-
ents and several classes of nonprescription drug products” (footnote omitted)); id.
at 627 (referencing “FDA activities designed to restrict the use of certain nonpre-
scription drug ingredients or certain classes of nonprescription drug products,
such as placing them on prescription”).
117. Cf. Am. Pub. Health Ass’n v. Veneman, 349 F. Supp. 1311, 1317 (D.D.C.
1972) (expressing concern about the FDA’s decision, once it established the mon-
ograph process, against publishing 260 reports solicited from the National Acad-
emy of Sciences-National Research Council (NAS-NRC) rating nonprescription
drugs in light of the fact that one “report on over-the-counter drugs indicates that
only 25% of such drugs are effective”); id. at 1317 n.19 (“The FDA has just released
for publication an NAS-NRC report on over-the-counter drugs, specifically cold
remedies, that was submitted to the FDA three years ago.  The report indicates that
many of the nation’s leading cold medications lack substantial evidence of effec-
tiveness and are subject to withdrawal.”).  In a set of regulations that largely pre-
dated the OTC drug review, the FDA demanded prescription status for more than
a dozen ingredients. See Reorganization and Republication, 40 Fed. Reg. 13,996,
14,034–37 (Mar. 27, 1975) (codified as amended at 21 C.F.R. §§ 250.12-.108).
118. See supra note 45.  Something like this happened, for instance, with a
popular acne ingredient after questions about its safety arose.  In 1985, the FDA
tentatively concluded that low concentrations of benzoyl peroxide qualified as
GRAS/E, but six years later it deferred final action on this ingredient until it could
resolve new concerns about possible carcinogenicity. See Topical Acne Drug Prod-
ucts for Over-the-Counter Human Use; Final Monograph, 56 Fed. Reg. 41,008,
41,008–09 (Aug. 16, 1991) (noting that animal studies suggested this ingredient
may promote tumors).  Although it allowed continued OTC marketing while it
awaited the results of promised new studies, the FDA proposed warnings about
avoiding sun exposure, see Topical Drug Products Containing Benzoyl Peroxide;
Required Labeling, 60 Fed. Reg. 9554, 9557 (Feb. 17, 1995) (to be codified at 21
23
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contrast to the FDA’s evident willingness to jettison questionable nonpre-
scription ingredients that it has not previously green-lighted, this Article
focuses on drugs that have gotten the agency’s blessing for OTC use and
asks why such basic judgments about appropriate categorization seem to
become largely unalterable.
IV. TRYING TO PUT THE GENIE BACK IN THE (PRESCRIPTION) BOTTLE
When it initiated the OTC drug review in the early 1970s, the FDA
plainly envisioned that switches might go in either direction.119  It also
viewed such judgments as not “frozen in time.”120  In 2000, when it an-
nounced a public hearing about its policies regarding Rx-to-OTC switches,
the agency asked tangentially whether “older therapies that may provide
less benefit or more risk [should] be removed from the OTC market.”121
Almost two decades later, it has not offered an answer, though the FDA’s
longstanding pattern of behavior suggests a lack of interest in unswitching
any drugs that it has moved to nonprescription status.122
C.F.R. § 201.318(b)), and in the preamble it suggested possibly sharing informa-
tion about tumor risks with consumers through leaflets inserted in product pack-
ages, see id. at 9555–56 (helpfully supplying text to use); see also id. at 9556–57
(strongly encouraging manufacturers to voluntarily relabel their products even
before finalization of the rule).  In the end, after the submission of reassuring
studies, the FDA added the ingredient to the OTC monograph and decided
against requiring any disclosures about its earlier safety concerns. See Final Rule,
Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to
Drug Facts Format; Topical Acne Drug Products for Over-the-Counter Human
Use, 75 Fed. Reg. 9767, 9776 (Mar. 4, 2010) (codified at 21 C.F.R. pt. 333).
119. See Procedures for Classification of Over-the-Counter Drugs, 37 Fed. Reg.
9464, 9470 (May 11, 1972) (¶ 70); Hutt, supra note 16, at 429–30 (quoting the FDA
Chief Counsel as explaining at the outset of the process that it would be about
“‘confirming the OTC status [of every drug under review], perhaps changing
some from prescription to OTC or perhaps going the other way and changing
some from OTC to prescription’”); id. at 430 (same, in instructing review panels:
“ ‘[T]he opposite is also true.  If there are over-the-counter drugs today that you
think should be switched to prescription, then we want you to give us that advice
also.’”); cf. Fisher, supra note 30, at 611 (“As the [OTC Drug] Review progressed, it
became clear that advisory review panels would recommend switching an apprecia-
ble number of ingredients from prescription to nonprescription status, but not
vice versa.”).
120. See Hutt, supra note 16, at 431 (“Consideration of the proper status of
drugs is inherently transitory.”); see also id. at 433 (“Congress recognized [in 1951]
that the determination of prescription/nonprescription status would never be
static, but must continually evolve on the basis of new information.”).
121. Public Hearing, Over-the-Counter Drug Products, 65 Fed. Reg. 24,704,
24,705 (Apr. 27, 2000).
122. Arguably, the agency’s review of substances used in food reflects a similar
tendency. See Lars Noah & Richard A. Merrill, Starting from Scratch?: Reinventing the
Food Additive Approval Process, 78 B.U. L. REV. 329, 382–85 (1998) (explaining that,
when new safety concerns arise about substances previously identified as “generally
recognized as safe” (GRAS), the FDA moves them into an “interim” food additive
category where they may remain indefinitely); see also Monica Eng, Who Tests the
Safety of New Ingredients in Food?; Too Often, U.S. Lets Manufacturers Make the Call on
Their Own Products, Critics Say, CHI. TRIB., Aug. 26, 2012, at A1 (“[A] few substances
24
Villanova Law Review, Vol. 63, Iss. 3 [2018], Art. 1
https://digitalcommons.law.villanova.edu/vlr/vol63/iss3/1
2018] OTC TO PRESCRIPTION STATUS 379
No doubt this reluctance to revisit judgments about suitability for
OTC marketing reflects skewed incentives faced by most of the interested
parties.123  Although legislative action occasionally forces the issue, it
might take broader reforms of the stark distinction between prescription
and nonprescription status to overcome the striking disinclination to re-
visit an Rx-to-OTC switch.  Alternatively, the prospect of tort liability might
incentivize sellers to restrict consumer access, though the defense of im-
plied federal preemption as presently configured would stand in the way
of efforts by plaintiffs to employ negligent marketing theories of recovery.
A. Lack of Incentives to Use Available Regulatory Mechanisms
First, the FDA might not relish the procedural obstacles presented by
trying to unravel an Rx-to-OTC switch.  The Durham-Humphrey Amend-
ment had called for doing so “by regulation,”124 which represents a route
that this agency increasingly prefers to avoid whenever possible.125  As
demonstrated by the serious delays that it has encountered in finalizing
the OTC monographs, rulemaking hardly offers an expeditious mecha-
nism for responding to serious new risk information.  Indeed, the FDA
recently has preferred issuing technically non-binding guidance docu-
ments to call for revisions in the labeling of nonprescription products.126
Although switching the status of products governed by OTC
monographs seemingly would necessitate amending the rules, prescrip-
tion drugs switched through the NDA process instead could get switched
back by amending the revised license.  Although the sponsor of such a
initially considered GRAS have later been found to pose health risks and were
subsequently banned by the FDA.  The most recent of these decisions was in 1986,
when the FDA prohibited the use of sulfites as a preservative on raw produce due
to severe allergic reactions in those sensitive to sulfites.”).
123. Cf. Joshua P. Cohen et al., Switching Prescription Drugs to Over the Counter,
330 BRIT. MED. J. 39, 39 (2005) (“Switches are motivated mainly by three factors:
pharmaceutical firms’ desire to extend the viability of brand names; attempts by
healthcare funders to contain costs; and the self care movement.  Making drugs
available over the counter affects a large number of stakeholders . . . .”); Dennis
Cauchon, Better Drugs May Be Stuck Behind Counter: Makers Prefer Slow Route to OTC
Market, USA TODAY, June 27, 2000, at 9D; Elyse Tanouye & Thomas M. Burton,
More Firms “Switch” Prescription Drugs to Give Them Over-the-Counter Status, WALL ST. J.,
July 29, 1993, at B1.
124. See 21 U.S.C. § 353(b)(3) (2012). But cf. Tummino v. Hamburg, 936 F.
Supp. 2d 162, 197–98 (E.D.N.Y. 2013) (suggesting that it might not necessitate
rulemaking, though focusing only on an Rx-to-OTC switch and of a product with
an approved NDA rather than subject to an existing OTC monograph).
125. See Lars Noah, Governance by the Backdoor: Administrative Law(lessness?) at
the FDA, 93 NEB. L. REV. 89, 94-97 (2014).
126. See, e.g., Recommended Warning for Over-the-Counter Acetaminophen-
Containing Drug Products and Labeling Statements Regarding Serious Skin Reac-
tions; Guidance for Industry, 82 Fed. Reg. 3332 (Jan. 11, 2017); Over-the-Counter
Pediatric Oral Liquid Drug Products Containing Acetaminophen; Guidance for
Industry, 80 Fed. Reg. 46,588 (Aug. 5, 2015); see also Noah, supra note 125, at 103,
113–22 (detailing the FDA’s shift toward guidance-making).
25
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nonprescription drug might resist and exercise its right to demand a hear-
ing,127 the FDA has various ways of short-circuiting this adjudicatory pro-
cess.128  In either case, however, a lack of resources may pose the biggest
obstacle.  Chronic underfunding exists for the OTC division, at least rela-
tive to those units that review new prescription drugs because only they get
user fee proceeds.129  An Rx-to-OTC switch accomplished through a sup-
plemental NDA would require payment by the sponsor of at least $1.2 mil-
lion,130 but apparently no one other than Congress would foot the bill for
unswitching.
Manufacturers would have no particular incentives to move a product
back into prescription status.  In contrast, as patents and non-patent regu-
latory exclusivities expire on a prescription drug, which means that com-
petitors introducing lower-cost generics threaten to take most of the
brand-name company’s market share, a switch to OTC status provides
manufacturers with various means of extending their revenue streams.131
First, an OTC switch may entitle the sponsor to additional protection
against generic competition: if the FDA required the sponsor to conduct
additional studies in order to support approval, then the successful appli-
127. See Noah, supra note 11, at 385, 387.
128. See Noah, supra note 125, at 123 (“Congress has delegated to the agency
increasingly elaborate licensing powers, but these also came with demanding pro-
cedures.  The FDA has, however, deployed these various tools in creative ways . . . .”
(footnote omitted)); Lars Noah, The Little Agency That Could (Act with Indifference to
Constitutional and Statutory Strictures), 93 CORNELL L. REV. 901, 911–12, 914 n.73
(2008).
129. See Kate Sheridan, These Companies Are Eager to Pay FDA Fees; Goal Is Fast
Reviews of OTC Products, BOS. GLOBE, Aug. 25, 2017, at B9.
130. See Prescription Drug User Fee Rates for Fiscal Year 2018, 82 Fed. Reg.
43,244, 43,247 tbl.7 (Sept. 14, 2017) (noting that this fee represents half the
charge for applications that require the submission of clinical data).  If the license
holder initiated the process of unswitching, then they would file another NDA
supplement and again pay this user fee.
131. See Cohen et al., supra note 123, at 40 (discussing loratadine and
omeprazole); Holly M. Spencer, Comment, The Rx-to-OTC Switch of Claritin, Allegra,
and Zyrtec: An Unprecedented FDA Response to Petitioners and the Protection of Public
Health, 51 AM. U. L. REV. 999, 1023–24, 1038–41 (2002); Milt Freudenheim, Rear-
ranging Drugstore Shelves: More Products Shift to Nonprescription, N.Y. TIMES, Sept. 27,
1994, at D1; Gabriella Stern & Rose Gutfeld, Vote Sets Back P&G, Syntex on Analgesic,
WALL ST. J., June 3, 1993, at B1 (“Most big pharmaceutical companies are trying to
switch to the over-the-counter category as a source of new revenue at a time when
prescription drug revenues are under pressure.”).  Other reasons that sellers might
favor an Rx-to-OTC switch have, however, faded with time. See Noah, supra note
11, at 380 n.110 (“[N]ow that manufacturers enjoy the freedom to advertise pre-
scription pharmaceuticals directly to consumers (coupled with the spread of insur-
ance coverage for prescription drugs), many of the older incentives to secure OTC
status appear to have vanished.”).  Recent developments in products liability doc-
trine have created disincentives to switching. See id. at 378–83; id. at 364 (“[A]n
Rx-to-OTC switch might increase a seller’s exposure to liability”); see also infra Part
IV.C (elaborating).  Nonetheless, when it opts to pursue a switch, the sponsor must
believe that enough of an upside remains to counterbalance the possibility of en-
hanced tort exposure.
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cant would receive an additional three-year period of market exclusiv-
ity.132  Second, with or without this extended protection, an OTC switch
means that generics could compete only in the nonprescription market-
place, clearing the way for the brand-name sponsor to introduce a pur-
portedly new and improved product in the prescription marketplace
without fear of getting undercut by generic versions of their original
drug.133  Neither one of these tactical maneuvers, however, operates in
the other direction, so brand-name companies would see little to gain
from moving their product back to prescription status—generic competi-
tors would automatically tag along in that case.134
In addition, switching affects regulatory jurisdiction over the advertis-
ing of these products: the FDA has the authority to supervise promotional
campaigns for prescription drugs,135 while the Federal Trade Commission
(FTC) supervises nonprescription drug advertising.136  For the most part,
the Commission’s standards offer somewhat greater flexibility than those
132. See Apotex, Inc. v. Shalala, 53 F. Supp. 2d 454, 458 & n.4 (D.D.C. 1999);
Berenson, supra note 51, at C1 (reporting that Prilosec had received this additional
period of marketing exclusivity); see also Upjohn Co. v. Kessler, 938 F. Supp. 439,
443–45 (W.D. Mich. 1996) (declining to issue a preliminary injunction where the
manufacturer of Rogaine® (minoxidil) failed to establish a likelihood of success on
the merits of its claim that the FDA should have granted its request for market
exclusivity after an Rx-to-OTC switch).  Moreover, once any exclusivity period ex-
pires for a product switched OTC, state laws requiring generic substitution only
apply to pharmacists dispensing prescription drugs, which means that brand loy-
alty by consumers will allow the sponsor to retain greater market share even when
competing against lower-priced products offered by competitors.
133. See, e.g., Francesca Kritz, A Side Effect Felt in the Wallet: With Generic Prilosec
Due, the $6 Billion Drug’s Maker Offers a High-Priced Successor, WASH. POST, Mar. 13,
2001, at T6; Rita Rubin, Claritin Going OTC: Will Heir Be a Prescription for Success?,
USA TODAY, Apr. 23, 2002, at 11D; see also Lars Noah, Product Hopping 2.0: Getting
the FDA to Yank Your Original License Beats Stacking Patents, 19 MARQ. INTELL. PROP.
L. REV. 161, 168–69 (2015).  If, however, the FDA initially rejects a switch petition
and generic competitors enter the prescription market, then the brand-name com-
pany may not bother trying again even if subsequently produced evidence would
amply support a transition to OTC status. See Noah, supra note 11, at 363–64 n.26
(explaining that rejection of an OTC switch petition “creates a ‘prescription or-
phan,’” and concluding that “the alignment of the various parties’ interests after
the entry of generic prescription substitutes results in a suboptimal outcome”).
134. Insulin does not represent an exception.  Long available as an OTC drug
notwithstanding difficulties with self-diagnosis and administration, see Hutt, supra
note 16, at 436–37, newer versions that enjoyed patent protection require a pre-
scription, see Fast-Acting Insulin Approved, N.Y. TIMES, June 18, 1996, at C7; see also
Jeremy A. Greene & Kevin R. Riggs, Why Is There No Generic Insulin? Historical Ori-
gins of a Modern Problem, 372 NEW ENG. J. MED. 1171, 1173–74 (2015).
135. See 21 U.S.C. § 352(n) (2012); see also Lars Noah, Advertising Prescription
Drugs to Consumers: Assessing the Regulatory and Liability Issues, 32 GA. L. REV. 141,
142 & n.6, 145–49 (1997).
136. See 15 U.S.C. § 52(a) (2012); Sandoz Pharm. Corp. v. Richardson-Vicks,
Inc., 902 F.2d 222, 227 (3d Cir. 1990) (“[T]he FDA regulates the labeling of OTC
drugs while the FTC monitors the advertising for these drugs.”).
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of the FDA.137  Drug manufacturers contemplating a switch back to pre-
scription status presumably would hesitate before again subjecting their
marketing campaigns to the FDA’s scrutiny.
Finally, to the extent that health insurers have become interested in
advocating Rx-to-OTC switches,138 which would lessen their covered
charges for prescribed drugs and affiliated physician visits,139 they would
have no reason to want this process to work in the opposite direction.140
Insofar as government payers offer drug benefits, their incentives presum-
ably run parallel with those of private insurers.141  At the federal level, this
means that the Centers for Medicare and Medicaid Services (CMS)—a sis-
137. See Jeremy A. Greene et al., Letter, Changes in Direct-to-Consumer Pharma-
ceutical Advertising Following Shifts from Prescription-Only to Over-the-Counter Status, 308
JAMA 973 (2012); Anne V. Maher & Lesley Fair, The FTC’s Regulation of Advertising,
65 FOOD & DRUG L.J. 589, 602–03 (2010) (“For marketers accustomed to FDA’s
regulatory approach, the FTC’s law enforcement framework may seem curious.
Whereas FDA has promulgated detailed regulations relating to the advertising of
prescription drugs, the FTC has promulgated no specific rules on the advertising
of the health-related products for which it has primary responsibility.” (footnote
omitted)); id. at 605–14 (discussing the Commission’s substantiation doctrine); see
also Fisher, supra note 30, at 621–24 (describing decisions by the FTC against the
adoption of sweeping restrictions on OTC drug advertising).  Conversely, the Com-
mission may impose more sweeping sanctions for regulatory infractions. See, e.g.,
Novartis Corp. v. FTC, 223 F.3d 783, 786–89 (D.C. Cir. 2000) (rejecting a chal-
lenge to a corrective advertising order for a nonprescription analgesic product);
FTC v. Pantron I Corp., 33 F.3d 1088, 1097–103 (9th Cir. 1994) (sustaining an
enforcement action for false advertising against the seller of a baldness remedy);
see also Maher & Fair, supra, at 614–22 (discussing the range of remedies available
to the FTC).
138. See Spencer, supra note 131, at 1000–04 (providing background on an
effort to have the FDA switch three nonsedating prescription antihistamines, and
explaining that the agency never before had considered such a petition filed by an
insurer and over the objections of the manufacturer); Leila Abboud, Firms Gird for
Drug-Cost Fight: FDA May Force Over-the-Counter Sales of Some Allergy Medicines, WALL
ST. J., May 6, 2003, at A4 (“Insurance companies—which don’t reimburse policy-
holders for over-the-counter medicines—love the idea of requiring that drugs be
sold without prescriptions as much as pharmaceuticals makers hate it . . . .”).
139. See Spencer, supra note 131, at 1001–02 & n.12, 1021, 1026–29.
140. See Noah, supra note 11, at 361 (“If causing drowsiness made the older
antihistamines more dangerous, then perhaps WellPoint [Health Networks, the
parent company of Blue Cross and Blue Shield of California] should have urged
the FDA to move them to prescription status or withdraw them from the market
altogether.  (Of course . . . that might have increased its tab for the [nonsedating]
Rx products.)” (footnote omitted)).
141. See Rita Rubin, FDA’s Push to Switch Antihistamines to Over-the-Counter Raises
Eyebrows, USA TODAY, Apr. 24, 2003, at 9D (“Now that the Bush administration has
promised to add a prescription drug benefit to Medicare, some skeptics wonder
whether the FDA is looking to save the government money by taking antihista-
mines out of the lineup of covered medications.”); see also Cohen et al., supra note
123, at 39 (doubting suggestions that a similar impetus accounted for the recent
switch of a statin drug in the UK, but suggesting that it explains the switch of
omeprazole in Sweden); Richard W. Stevenson, Warner-Lambert in Two British Deals,
N.Y. TIMES, July 29, 1993, at D5 (noting a drug industry “belief that as governments
look for ways to reduce health care costs, they will be quicker to approve nonpre-
scription versions of drugs”).
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ter agency of the FDA,142 which is also housed within the U.S. Department
of Health and Human Services (HHS)—might well oppose any efforts to
promote the public health by moving OTC drugs to prescription status
because that would increase program costs.  Indeed, contemporaneously
with adoption of the Medicare drug benefit (Part D), the FDA’s proposed
FY2004 budget suggested that it would “become more proactive” in this
area because Rx-to-OTC switches could “provide an expedient way to sig-
nificantly reduce consumer health care costs.”143
The incentives faced by patients/consumers point in varied direc-
tions.144  For the uninsured, OTC availability offers clear benefits in terms
of accessibility and affordability.  For those with health insurance and com-
prehensive drug benefits (or else taking tax deductions for their medical
expenses), prescription status may have somewhat greater appeal.145
Nonetheless, even if an OTC switch at first confronts the latter group with
higher out-of-pocket costs,146 patients previously prescribed a drug will be-
come accustomed to the convenience of purchasing these directly at
retail.147
142. See Lars Noah, Coerced Participation in Clinical Trials: Conscripting Human
Research Subjects, 62 ADMIN. L. REV. 329, 333 n.16 (2010) (noting that “both agen-
cies reside in the same cabinet-level department”).
143. Rita Rubin, FDA Seeks to Switch Over-Counter, USA TODAY, Apr. 23, 2003, at
1A (quoting language from the agency’s proposed budget); see also Kaufman, supra
note 21, at A1.
144. See Noah, supra note 11, at 377, 389 nn.154–55; Rook, supra note 52, at
100 (“At first glance, a drug’s switch . . . may allow [the consumer] to avoid a
doctor’s appointment which would save time and money, and the OTC incarna-
tion of the drug may cost less than its prescription version.  However, our insur-
ance and tax systems make the switch disadvantageous for many consumers.”).
145. See Rook, supra note 52, at 129 n.123 (“Relatively little data exists con-
cerning the number of employer-provided plans that cover OTC medication, and
there is virtually no explanation for why these drugs are almost never covered.”).
Aside from differentials in insurance coverage, patients may claim a tax deduction
for medical expenses, including uncovered expenses for prescription but not OTC
drugs (except for insulin), now exceeding 10% of their adjusted gross income. See
Tax Equity and Fiscal Responsibility Act of 1982, Pub. L. No. 97–248, § 202(b), 96
Stat. 324, 421 (codified as amended at 26 U.S.C.A. § 213(a)-(b) (2017)); see also
Rook, supra note 52, at 137 n.165 (“Almost every state that imposes a sales tax
exempts prescription drugs.”); Josh Barro, The Latest Sales Tax Controversy: Tampons,
N.Y. TIMES, Jan. 7, 2016, at A3; cf. Sandra Block, IRS Rulings Make Medical Flexible
Spending Accounts More Attractive, USA TODAY, Sept. 30, 2003, at 3B (reporting that
employers now can offer “flex accounts” that would include purchases of OTC
drugs among eligible expenses).
146. See Strom, supra note 11, at 1403 (explaining that after an Rx-to-OTC
switch “patients with insurance that covers medications face the paradox of in-
creased, rather than reduced, costs for their medications”); Milt Freudenheim,
Claritin’s Price Falls, but Drug Costs More, N.Y. TIMES, May 8, 2003, at C1; Christopher
Rowland, Over-the-Counter Versions Seen Raising Costs for Insured, BOS. GLOBE, Jan. 31,
2004, at A1.
147. See Brass, supra note 11, at 812 (referencing significant increases in sales
volume after an Rx-to-OTC switch).
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In short, it seems unlikely that any of the potentially interested parties
would want to press for unraveling an Rx-to-OTC switch.  Unless the FDA
takes seriously its public health mission and overlooks the hassles that it
would encounter in moving a product back to prescription status—includ-
ing likely objections from sponsors, insurers, consumers, and the various
elected officials who represent the interests of these parties—this problem
starts to appear largely intractable; deregulation then truly becomes a one-
way ratchet.148
B. Awaiting Ad Hoc Fixes by State and Federal Legislatures
By going back a century, one can find examples of drugs that moved
from what amounted to OTC status into the category of prescription-only
use, though these necessitated acts of Congress and hardly recommend
themselves as successful experiments.  For instance, in the course of imple-
menting the Eighteenth Amendment to the U.S. Constitution,149 Con-
gress passed the Volstead Act,150 which exempted from Prohibition
alcoholic beverages when prescribed by a physician.151  Similarly, five
years earlier, it effectively had moved opiates and cocaine into prescrip-
tion status,152 and a few years after the repeal of Prohibition Congress did
the same for marijuana.153  Not until 1970 did it impose a blanket prohibi-
148. Cf. Colin Bradley & Alison Blenkinsopp, Over-the-Counter Drugs: The Future
for Self Medication, 312 BRIT. MED. J. 835, 835–36 (1996) (repeatedly referring to
Rx-to-OTC switches as “deregulation”).  Strictly speaking, an Rx-to-OTC switch
does not free a product from regulation, but it does remove restrictions on access.
149. U.S. CONST. amend. XVIII (1920), repealed by U.S. CONST. amend. XXI,
§ 2 (1933).
150. National Prohibition Act, Pub. L. No. 66–66, 41 Stat. 305 (1919), repealed
by Pub. L. No. 74–347, 49 Stat. 872 (1935).
151. See id. tit. II, §§ 7–8, 41 Stat. at 310–11 (allowing for the medicinal use of
certain liquors only when prescribed by a physician who had a special permit and
only in strictly limited quantities); see also Lambert v. Yellowley, 272 U.S. 581,
589–97 (1926) (rejecting a constitutional challenge to this provision); cf. James
Everard’s Breweries v. Day, 265 U.S. 545, 558–63 (1924) (upholding the affiliated
prohibition against even purportedly medical uses of malt liquors); id. at 562
(“Congress determined, in effect, that intoxicating malt liquors possessed no sub-
stantial and essential medicinal properties which made it necessary that their use
for medicinal purposes should be permitted . . . .”).
152. See Harrison Narcotics Act, Pub. L. No. 63–223, §§ 2(a)&(b), 4, 38 Stat.
785, 786, 788 (1914) (repealed 1970); see also Linder v. United States, 268 U.S. 5,
17–23 (1925) (construing the statute narrowly so as not to intrude unduly on med-
ical practice).
153. See Marihuana Tax Act, Pub. L. No. 75–238, § 2(a)(3), 50 Stat. 551, 552
(1937) (repealed 1970) (specifying an annual tax for health professionals who dis-
pense, prescribe, or otherwise use this drug when treating their patients); id.
§ 6(b)(1)&(2), 50 Stat. at 553 (delegating authority to issue rules requiring main-
tenance of records in such cases); see also Noah, supra note 2, at 59 (pointing out
that the U.S. Pharmacopeia “had listed marijuana as a drug for almost a century
(until 1941), and prominent physicians had endorsed its use early in the twentieth
century for treating maladies such as migraine headaches”).
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tion on marijuana and certain other narcotics.154  More recently, however,
states began chipping away at the federal prohibition with medical mari-
juana initiatives,155 which depended on securing some form of physician
authorization.156  Although federal law has not changed,157 in some states
marijuana now resides in what amounts to OTC status.158
Contemporary responses to abused nonprescription drugs, at both
the federal and state level, suggest a somewhat more nuanced approach to
this problem.  Concerns about methamphetamine have prompted legisla-
tors and retailers to restrict access to OTC cough-cold products containing
the meth precursor pseudoephedrine.159  In 2006, Congress dictated “be-
hind-the-counter” status—though not limited to pharmacies—for prod-
ucts containing pseudoephedrine, but this statute sought to prevent
154. See Comprehensive Drug Abuse Prevention and Control Act of 1970,
Pub. L. No. 91–513, tit. II, § 202(c), 84 Stat. 1236, 1248–49 (codified as amended
at 21 U.S.C. § 812(c)) (listing marihuana in Schedule I(c)(10)); see also Noah,
supra note 19, at 177, 180–82 (discussing the decision to place marijuana in Sched-
ule I).
155. See Kevin P. Hill, Medical Marijuana for Treatment of Chronic Pain and Other
Medical and Psychiatric Problems: A Clinical Review, 313 JAMA 2474, 2475 (2015) (“23
states and the District of Columbia have enacted medical marijuana laws to facili-
tate access to marijuana as a treatment for a variety of medical conditions.”); id. at
2476–77 tbl.1 (summarizing these various laws). See generally Todd Grabarsky, Con-
flicting Federal and State Medical Marijuana Policies: A Threat to Cooperative Federalism,
116 W. VA. L. REV. 1 (2013); Robert A. Mikos, On the Limits of Supremacy: Medical
Marijuana and the States’ Overlooked Power to Legalize Federal Crime, 62 VAND. L. REV.
1421 (2009).
156. Some state laws avoid characterizing these as “prescriptions,” evidently to
provide a bit of cover for health care professionals. See Conant v. Walters, 309 F.3d
629, 634-36 (9th Cir. 2002) (distinguishing physician “recommendation” required
under California law from a “prescription”).  For a discussion of initial and gener-
ally antagonistic federal responses to the earliest state initiatives, see Noah, supra
note 19, at 151 & n.8, 181–83.
157. See Catherine Saint Louis, D.E.A. Refusal to Reclassify Marijuana Draws Crit-
icism, N.Y. TIMES, Aug. 12, 2016, at A13.  Congress recently (and only partially)
relented. See Consolidated Appropriations Act of 2017, Pub. L. No. 115–31, § 537,
131 Stat 135, 228 (providing that appropriations for the Department of Justice
cannot be used to prevent the implementation of medical marijuana laws in 44
listed states and the District of Columbia); United States v. McIntosh, 833 F.3d
1163, 1169–70, 1176–79 (9th Cir. 2016) (applying earlier versions of this appropri-
ations rider originally enacted in 2014).
158. See Paul Sullivan, Investors Discovering Big Returns in Cannabis, N.Y. TIMES,
Jan. 27, 2018, at B3 (“Twenty-nine states now allow marijuana for medical pur-
poses, while eight have legalized its recreational use.”). See generally Symposium,
One Toke Too Far? The Horizontal-Federalism Implications of Marijuana Legalization, 58
B.C. L. REV. 857 (2017).
159. See Leslie Earnest & Rong-Gong Lin II, Target Moves Sale of Cold Medica-
tions to Pharmacy, L.A. TIMES, Apr. 19, 2005, at C1; Margaret Webb Pressler, Retailers
Restrict Some Cold Medicines: Ingredient Can Be Used to Make Meth, WASH. POST, May
14, 2005, at A1.  PPA also worked as a meth precursor, but the FDA urged the
removal of this ingredient from OTC products on safety grounds at this same time.
See supra notes 111–14 and accompanying text.
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criminal diversion rather than any health risks to consumers.160  In the
face of continuing abuse, some states pursued stricter controls, including a
couple that moved pseudoephedrine into prescription status.161  In the
face of such access restrictions, several manufacturers of cough-cold prod-
ucts reformulated using phenylephrine.162  Retailers also have begun to
limit access to other OTC cough-cold products in response to problems
with teenagers purchasing them to get high.163
Perhaps it would make sense to codify the notion of a pharmacist-
controlled class of drugs to serve as a transitional step between prescrip-
tion and OTC status when switching a new category of prescription
pharmaceuticals.164  Other industrialized countries use just such an inter-
mediate category of products.165  Although historically the FDA emphati-
cally rejected proposals to create a “third class” of drugs,166 more recently
160. See Combat Methamphetamine Epidemic Act of 2005, Pub. L. No.
109–177, tit. VII, § 711(b), 120 Stat. 256, 257–61 (2006) (codified as amended at
21 U.S.C. § 830); see also Note, Cooking up Solutions to a Cooked up Menace: Responses
to Methamphetamine in a Federal System, 119 HARV. L. REV. 2508, 2517–18, 2524,
2526–27 (2006) (putting this law in context with earlier federal and state legisla-
tion).  Indeed, the FDA had opposed the legislation, arguing that it inappropri-
ately sacrificed the interests of consumers suffering from cold symptoms. See
Gardiner Harris, Fighting Methamphetamine, Lawmakers Reach Accord to Curb Sale of
Cold Medicines, N.Y. TIMES, Dec. 15, 2005, at A33.
161. See Lars Noah, State Affronts to Federal Primacy in the Licensure of Pharmaceu-
tical Products, 2016 MICH. ST. L. REV. 1, 20 & n.75; see also Christopher Wanjek, Gee,
Your Hair Smells Carcinogenic!; Why California Wants to Expose the Coal Tar in Dandruff
Shampoos—And Why the Industry Is Resisting, WASH. POST, Mar. 27, 2001, at T6 (“The
[FDA] acknowledges that coal tar is carcinogenic but says that the over-the-counter
coal-tar shampoos are safe . . . .  But in California, . . . [activists and the state’s
attorney general] are suing more than 20 manufacturers of coal-tar shampoos and
ointments to require them to place warning labels on their products—and ulti-
mately to sell them by prescription only.”).
162. See Jennifer Corbett Dooren, Decongestants Get Makeover to Keep Them over
the Counter, WALL ST. J., May 9, 2006, at D3 (adding that this ingredient is some-
what less effective than pseudoephedrine).
163. See Rebecca Dana, Household Medicine Abused by the Young; Trend Alarms
Activists, Officials, WASH. POST, Oct. 8, 2004, at A1 (highlighting “dextromethor-
phan, the active ingredient in cough medicines such as Robitussin”).
164. See Fisher, supra note 30, at 594 (“Recent ‘third class of drugs’ efforts
have arisen primarily because of the FDA’s switch in recent years of many ingredi-
ents to ‘nonprescription’ status . . . .”); id. at 628 (concluding, however, that this
would be unjustified); Morning-After Pill May No Longer Need Prescription, WALL ST. J.,
Nov. 25, 2003, at D4 (“[A]s OTC drugs evolve from quick symptom relief to more
complex therapy, the FDA is considering whether it’s also time to change how
some of them are sold, perhaps beginning ‘behind-the-counter’ sales for certain
nonprescription drugs . . . .”).
165. See Fisher, supra note 30, at 625–26 (noting that the U.S. “is one of the
few developed countries with only two classes of drugs,” but explaining that the
European systems reflect peculiar customs and other factors unrelated to safety);
see also Rita Rubin, Rx out of the Box, USA TODAY, Feb. 8, 2005, at 1D (“About half of
non-prescription drugs in the United Kingdom can be sold only where pharmacists
can supervise their sale . . . .”).
166. See Tummino v. Hamburg, 936 F. Supp. 2d 162, 183 (E.D.N.Y. 2013);
Final Order for Antacid and Antiflatulent Products Generally Recognized as Safe
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it has suggested greater openness to the idea.167  Most proponents of a
behind-the-counter category view it as providing a transitional (or half)
step from prescription to nonprescription status,168 but, as the experience
with pseudoephedrine demonstrates, it also may work in the opposite di-
rection, offering a handy compromise for those stakeholders unwilling to
move a drug entirely back into prescription status.169
C. Harnessing the Threat of Tort Liability to Drive Switchbacks
When proceeding with an Rx-to-OTC switch, pharmaceutical manu-
facturers face increased exposure to tort liability,170 both because patterns
and Effective and Not Misbranded, 39 Fed. Reg. 19,862, 19,864 (June 4, 1974)
(“[T]here is no health or safety justification for establishing a third class of drugs
at this time.”); OTC Drugs: Proposed General Conditions, 39 Fed. Reg. 19,880,
19,881 (June 4, 1974) (elaborating); U.S. CONG., GEN. ACCOUNTING OFFICE, PEMD-
95-12, NONPRESCRIPTION DRUGS: VALUE OF A PHARMACIST-CONTROLLED CLASS HAS
YET TO BE DEMONSTRATED, at 75–80 (1995) (concluding that little support exists
for an intermediate class of drug products available only on the recommendation
of pharmacists); Fisher, supra note 30, at 596 (“The federal government has often
considered and has consistently rejected the establishment of a third class of
drugs.”); id. at 596–604 (elaborating).
167. See Notice of Public Meeting, Behind the Counter Availability of Certain
Drugs, 72 Fed. Reg. 56,769 (Oct. 4, 2007) (seeking input about the merits of this
approach); see also Daniel Healey, Plan BTC: The Case for a Third Class of Drugs in the
United States, 63 FOOD & DRUG L.J. 375, 378 (2008).
168. See Fisher, supra note 30, at 593, 601–04; id. at 628 (explaining that this
“drives much of the current efforts by some to establish a third class of drugs”);
Healey, supra note 167, at 377 & n.20, 388; id. at 379 (“BTC status could also pro-
vide a ‘testing ground’ to accumulate more safety data in preparation for a full-
fledged OTC switch.”); id. at 384–85, 387 (focusing on cholesterol-lowering
statins).
169. See Healey, supra note 167, at 378; McGinley, supra note 109, at A3 (quot-
ing a medical expert as favoring behind-the-counter status for loperamide in the
event that the FDA’s revised labeling and calls for more cumbersome packaging
fail to guard against abuse of this antidiarrheal product).  If pharmacists become
responsible for the dispensing of formerly OTC drugs, then they would have a
better chance of catching potential interactions with any prescription drugs used
by a patient. Cf. Brass, supra note 11, at 814 (explaining that pharmacies do not
track OTC purchases); Betsy Sleath et al., Physician-Patient Communication About
Over-the-Counter Medications, 53 SOC. SCI. & MED. 357, 366 (2001) (“The trend to-
ward prescription-to-OTC switches will make it increasingly important for patients
to tell their physicians about their use of OTC medications, so . . . their providers
can help prevent potential drug interactions and adverse effects from occurring.”);
id. at 367 (“[I]ndividuals often fail to mention OTC products when they are asked
what medications they are taking, possibly because they are unaware of potential
adverse effects and/or drug interaction.”).
170. See Temin, supra note 7, at 353 (speculating that pharmaceutical manu-
facturers are not “anxious to increase their [liability] exposure by selling powerful
drugs on the over-the-counter market”); id. at 356 (“[D]rug companies are exceed-
ingly sensitive to the costs of being sued for the apparently negligent marketing of
their products.”); Daniel W. Whitney, Product Liability Issues for the Expanding OTC
Drug Category, 48 FOOD & DRUG L.J. 321, 349 (1993) (predicting that a switch to
OTC status “may be accompanied by a greater frequency of personal injury
claims”).
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of consumption change in ways that present heightened risks of inappro-
priate use and because of differences in applicable products liability doc-
trine.  For instance, courts typically apply a forgiving design defect
standard to prescription drug products,171 while sellers of nonprescription
drugs receive no special solicitude.172
In addition, the learned intermediary doctrine, which substantially
limits the availability of inadequate warning claims against sellers of pre-
scription drugs by imposing a duty to warn only health care professionals,
falls out of the picture.173  When drug products can be purchased without
a prescription, the manufacturer’s duty to warn runs directly to consumers
and requires that the information make sense to a layperson.174  In mak-
ing an Rx-to-OTC switch, the FDA invariably abridges the package insert,
which means that some of the risk information previously communicated
to physicians will not appear on the label of the nonprescription drug.
When a consumer then experiences such a known but undisclosed side
171. See Lars Noah, This Is Your Products Liability Restatement on Drugs, 74
BROOK. L. REV. 839, 842–84 (2009).
172. See, e.g., Brown v. Johnson & Johnson, 64 F. Supp. 3d 717, 721–23 (E.D.
Pa. 2014) (rejecting the defendants’ motion for summary judgment on claims that
an OTC ibuprofen product intended for use in children suffered from a design
defect because it allegedly was less safe than its enantiomer dexibuprofen, which
the FDA previously had declined to approve but might do so if a sponsor con-
ducted further testing); see also RESTATEMENT (THIRD) OF TORTS: PRODS. LIAB. § 2
cmt. k (1998).  With regard to design defect claims, this makes sense because the
Restatement’s specialized standard asks whether a fully informed health care profes-
sional would select a prescription drug for any class of patients. See id. § 6(c); see
also James A. Henderson, Jr. & Aaron D. Twerski, Drug Designs Are Different, 111
YALE L.J. 151, 156, 170–73, 178–79 (2001) (emphasizing physician involvement to
justify the distinctive doctrinal treatment of prescription products); id. at 169
(“[S]uch differentiation [in design defect standards based on users] is not possible
for nonprescription products, which are available to everyone on the open mar-
ket.”).  Some commentators have, however, questioned such second-class treat-
ment for nonprescription products. See Noah, supra note 11, at 380 (“[T]hese
protections also might extend to increasingly potent and useful nonprescription
drugs. . . .  In an earlier era, when OTC drugs offered marginal symptomatic relief
and generally posed only trivial risks, it made sense to apply the same [design
defect] standard used for cosmetics, appliances, and other consumer goods.”);
Whitney, supra note 170, at 324 (“[I]t is difficult to fathom how a Rx drug would
lose its social utility merely because it is being made available OTC.”).
173. See Lofton v. McNeil Consumer & Specialty Pharm., 682 F. Supp. 2d 662,
679 (N.D. Tex. 2010) (“The court will not . . . apply this exception to an over-the-
counter drug, even if at one time ibuprofen was a prescription drug.”); cf. Whitney,
supra note 170, at 329–30 (arguing that the doctrine should remain applicable in
cases where a doctor prescribes an OTC drug).
174. See, e.g., O’Gilvie v. Int’l Playtex, Inc., 821 F.2d 1438, 1441–42 (10th Cir.
1987); Hahn v. Sterling Drug, Inc., 805 F.2d 1480, 1482–83 (11th Cir. 1986); see
also Brown, 64 F. Supp. 3d at 720–21 (rejecting the defendants’ motion for sum-
mary judgment on claims that the manufacturer of an OTC ibuprofen product
intended for use in children had failed to warn consumers of the risks of Stevens-
Johnson Syndrome and toxic epidermal necrolysis, though concluding that there
was no separate duty to warn physicians).
34
Villanova Law Review, Vol. 63, Iss. 3 [2018], Art. 1
https://digitalcommons.law.villanova.edu/vlr/vol63/iss3/1
2018] OTC TO PRESCRIPTION STATUS 389
effect, the manufacturer may find itself hard-pressed to defend against a
failure-to-warn claim.175
As presently configured, therefore, tort law should make a pharma-
ceutical manufacturer think twice before switching a prescription drug to
OTC status.  Assuming, however, that a company has confidence in its
product’s relatively benign nature and the capacity for labeling to instruct
laypersons about safe use, other incentives will weigh more heavily in favor
of pursuing such a switch.  Moreover, normal rules of causation would still
apply and should protect manufacturers against liability claims for unsub-
stantiated side effects.176  Finally, no liability should attach for failures to
design against or warn of previously unknowable or rare risks such as aller-
gic reactions.177
What, however, if the risk-benefit balance sours at a later date?  The
FDA’s failure to revisit its original assent to an Rx-to-OTC switch would not
necessarily prevent plaintiffs from pressing design defect or inadequate
warning claims,178 and manufacturers would find it difficult to raise a fed-
eral preemption defense.  Although Congress expressly displaced state
regulation with respect to OTC drugs, it paired that provision with a clause
saving tort claims.179  This would not invariably foreclose invoking implied
175. See J. Warren Rissier, Note, The FDA’s Proposed Labeling Rules for Over-the-
Counter Drugs and Preemption of State Tort Law, 71 S. CAL. L. REV. 1387, 1399 (1998)
(“OTC drug manufacturers are especially vulnerable to state tort lawsuits for fail-
ure to warn since ‘switch’ products will inevitably have fewer warnings on the OTC
drug label than previously included on the prescription label.”); id. at 1392,
1399–400 (elaborating on the reasons that labeling becomes abridged, and using
the switched H2 blocker Pepcid® to illustrate); see also Noah, The Imperative to Warn,
supra note 34, at 338 (describing differences in consumer and professional label-
ing for otherwise identical drugs).
176. See, e.g., Porter v. Whitehall Labs., Inc., 9 F.3d 607, 614–16 (7th Cir.
1993) (ibuprofen and kidney failure); Wade-Greaux v. Whitehall Labs., Inc., 874 F.
Supp. 1441, 1477–85 (D.V.I. 1994) (Primatene® and birth defects); Burroughs
Wellcome Co. v. Crye, 907 S.W.2d 497, 499–500 (Tex. 1995) (reversing judgment
for the plaintiff on failure-to-warn and related claims because of insufficient evi-
dence that the OTC topical antibiotic spray Polysporin® caused frostbite injuries);
supra note 111 (discussing the PPA litigation); see also E.R. Squibb & Sons v. Cox,
477 So. 2d 963, 970–71 (Ala. 1985) (holding that an insulin manufacturer’s al-
leged failure to warn could not have caused any injury where the consumer admit-
ted to discarding the product insert without reading it).
177. See, e.g., Burlison v. Warner-Lambert Co., 842 F.2d 991 (8th Cir. 1988)
(anaphylactic reaction to menthol in cough drops); Daley v. McNeil Consumer
Prods. Co., 164 F. Supp. 2d 367, 373–74 (S.D.N.Y. 2000) (Lactaid®); Griggs v.
Combe, Inc., 456 So. 2d 790, 792 (Ala. 1984) (reaction to benzocaine in Vagisil®).
178. See Lars Noah, Rewarding Regulatory Compliance: The Pursuit of Symmetry in
Products Liability, 88 GEO. L.J. 2147, 2150–52, 2155–58 (2000) (explaining that sat-
isfying FDA requirements generally does not serve as a defense).
179. See 21 U.S.C. § 379r (2012); Over-the-Counter Drugs: Labeling Require-
ments, 64 Fed. Reg. 13,254, 13,272 (Mar. 17, 1999); cf. Green v. BDI Pharm., 803
So. 2d 68, 74–75 (La. Ct. App. 2001) (finding express preemption of a failure-to-
warn claim involving an OTC ephedrine product, ignoring entirely the impact of
the savings clause).  Because the preemption provision applicable to medical de-
vices did not include a savings clause, courts find express preemption of tort
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preemption,180 but the U.S. Supreme Court has largely refused to allow
such a defense against failure-to-warn claims involving drugs with ap-
proved NDAs because an FDA regulation allows unilateral revisions to risk
labeling by the brand-name company holding such a license.181  Preemp-
tion aside, manufacturers might come to miss the relative shelter from
expansive products liability claims reserved for prescription drugs and
consider seeking a return to that status.
Moreover, even if they encountered obstacles to asserting design de-
fect and failure-to-warn claims against manufacturers of OTC drugs that
caused injury, plaintiffs might try to pursue a “negligent marketing”
claim.182  Although this theory of liability remains largely untested, it may
claims, see Riegel v. Medtronic, Inc., 552 U.S. 312, 322–30 (2008), including those
brought against devices sold directly to consumers, see, e.g., Papike v. Tambrands,
Inc., 107 F.3d 737, 740–42 (9th Cir. 1997) (tampons); Murphy v. Playtex Fam.
Prods. Corp., 176 F. Supp. 2d 473, 482–83 (D. Md. 2001) (same), aff’d, 69 F. App’x
140 (4th Cir. 2003) (per curiam); cf. Buckman v. Plaintiffs’ Legal Comm., 531 U.S.
341, 347–53 (2001) (finding a fraud-on-the-FDA claim involving review of a medi-
cal device impliedly preempted).  In contrast, Congress has largely remained silent
about preemption with respect to prescription drugs. See Noah, supra note 161, at
8–9.
180. An effort to use California’s Proposition 65, which Congress also had
saved from the operation of the express preemption clause, to require reproduc-
tive toxicity warnings on OTC smoking cessation products foundered on the basis
of implied preemption because it would frustrate the purposes underlying the
FDA’s decision not to mention this risk. See Dowhal v. SmithKline Beecham Con-
sumer Healthcare, 88 P.3d 1, 9–11, 15 (Cal. 2004); see also Sandhya Somashekhar,
Smoking-Cessation Restrictions to Be Eased, WASH. POST, Apr. 2, 2013, at A2 (reporting
that, at the urging of public health advocates and in order to encourage efforts to
quit, the FDA further watered down the instructions for guarding against nicotine
overdose).
181. See Wyeth v. Levine, 555 U.S. 555, 567–81 (2009); see also Reckis v. John-
son & Johnson, 28 N.E.3d 445, 455–61 (Mass. 2015) (rejecting an implied preemp-
tion defense to claims that the manufacturer of an OTC ibuprofen product had
failed to warn consumers of the risks of Stevens-Johnson Syndrome and toxic epi-
dermal necrolysis).  Implied preemption should, however, bar design defect claims
against manufacturers of FDA-approved drugs. See Noah, supra note 161, at 29–34.
Furthermore, implied preemption might also defeat failure-to-warn claims involv-
ing OTC drugs governed by monographs as opposed to NDAs—after all, under
these classwide regulations, the FDA (rather than any particular sponsor) dictates
the precise content of labeling and allows essentially no deviations. See 21 C.F.R.
§ 330.1(c)(2)(i), (j) (2018); see also Noah, The Imperative to Warn, supra note 34, at
321 (“Even when it revised its policy to allow for greater flexibility in labeling, FDA
continued to demand verbatim adherence to any warnings prescribed in the
regulations.”).
182. See Lars Noah, Platitudes About “Product Stewardship” in Torts: Continuing
Drug Research and Education, 15 MICH. TELECOMM. & TECH. L. REV. 359, 385–91
(2009); cf. Richard C. Ausness, Tort Liability for the Sale of Non-Defective Products: An
Analysis and Critique of the Concept of Negligent Marketing, 53 S.C. L. REV. 907, 909–10,
915–16, 944–46 (2002); id. at 939 (“Just a few years ago, it appeared that negligent
marketing was about to become a powerful tool in products liability litigation, par-
ticularly where the products involved were not ‘defective’ in the traditional
sense.”); id. at 965 (concluding for a variety of reasons that courts should decline
to recognize such claims).
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help to provide the impetus needed to overcome the absence of other
incentives to unravel a switch.  If an OTC drug with otherwise unassailable
design and labeling causes an injury, then the victim might argue that the
product should have been made available only under professional medical
supervision and never sold directly to consumers.183  Such a claim would
represent something of a hybrid between more traditional defects in de-
sign and labeling, challenging a manufacturer’s choice about the appro-
priate channels for distributing potentially hazardous goods, such as items
not appropriate for use by youngsters,184 in a way that resembles novel
(and so far largely unsuccessful) theories asserted against gun manufactur-
ers.185  In particular, such claims find their closest parallel in lawsuits al-
leging that manufacturers of certain types of weapons or ammunition
should not have sold these products to civilians, instead limiting their dis-
tribution to law-enforcement professionals and the military.186
183. See Howard Latin, “Good” Warnings, Bad Products, and Cognitive Limita-
tions, 41 UCLA L. REV. 1193, 1271 (1994) (“Why should the presence of a ‘good’
warning, no matter how explicit, prevent courts from considering the value of al-
ternative marketing strategies in light of the common tendency of people to
overuse over-the-counter drugs that provide relief from chronic ailments?”);
Whitney, supra note 170, at 328–29 (speculating, without further elaboration, that
consumers injured by a nonprescription drug may argue that it “was so dangerous
no warning would be sufficient” and that “the drug should not be available OTC
because of the need for supervision and control by a qualified physician”); see also
Michael v. Warner/Chilcott, 579 P.2d 183, 189–90 (N.M. Ct. App. 1978) (Her-
nandez, J., concurring) (concluding that, although no reasonable jury could have
found an inadequacy in the warning of kidney damage from prolonged use of a
decongestant product containing phenacetin, the plaintiff’s expert testimony that
this drug should have been restricted to prescription status provided sufficient evi-
dence to support his design defect claim); cf. Ramirez v. Plough, Inc., 863 P.2d
167, 177–78 (Cal. 1993) (rejecting the plaintiff’s claim that the defendant should
not have marketed OTC children’s aspirin because of the risk of Reye’s syndrome
and the availability of safer substitutes).
184. See, e.g., Moning v. Alfono, 254 N.W.2d 759, 762 (Mich. 1977) (holding
that a jury should resolve negligence claims against the manufacturer, wholesaler
and retailer of slingshots marketed directly to children); id. at 771 (“The issue in
the instant case is not whether slingshots should be manufactured, but the nar-
rower question of whether marketing slingshots directly to children creates an un-
reasonable risk of harm.”); cf. First Nat’l Bank of Dwight v. Regent Sports Corp.,
803 F.2d 1431, 1435 (7th Cir. 1986) (rejecting failure-to-warn and negligent mar-
keting claims against the manufacturer of metal-tipped lawn darts sold as appropri-
ate for adults only, but allowing claims for violations of federal regulations
prohibiting sales of such products through toy stores and similar retail outlets).
185. See, e.g., Merrill v. Navegar, Inc., 28 P.3d 116, 119 (Cal. 2001); Chicago v.
Beretta U.S.A. Corp., 821 N.E.2d 1099, 1148 (Ill. 2004); Hamilton v. Beretta U.S.A.
Corp., 750 N.E.2d 1055, 1059 (N.Y. 2001); see also Jean Macchiaroli Eggen & John
G. Culhane, Gun Torts: Defining a Cause of Action for Victims in Suits Against Gun
Manufacturers, 81 N.C. L. REV. 115, 204–09 (2002). But see Ileto v. Glock Inc., 349
F.3d 1191, 1201–09 (9th Cir. 2003) (allowing a negligent marketing claim to pro-
ceed); City of Cincinnati v. Beretta U.S.A. Corp., 768 N.E.2d 1136, 1141 (Ohio
2002) (allowing a municipality to pursue such claims).
186. See, e.g., McCarthy v. Olin Corp., 119 F.3d 148, 152, 156–57 (2d Cir.
1997) (noting, in the course of rejecting such a claim, that the manufacturer of
Black Talon ammunition subsequently limited sales to professionals); id. at 163
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Even if the FDA had approved an Rx-to-OTC switch, an injured con-
sumer might argue that a reasonable drug manufacturer should never
have undertaken marketing directly to laypersons.  If confronted with the
response that it would violate federal law to sell an OTC drug product with
prescription-only labeling,187 a plaintiff instead might argue that the man-
ufacturer acted negligently in failing to request that the agency allow it to
switch a dangerous drug to prescription status.  Nonetheless, unlike other
revisions of labeling that the manufacturer of an FDA-approved drug
might undertake unilaterally, the fact that such a switch in status would
necessitate waiting for the agency’s permission should bar liability for neg-
ligent marketing on grounds of implied federal preemption.188  Thus,
even if courts seemed otherwise receptive to this novel theory, plaintiffs
would have to find some way of getting around preemption before tort law
offers much help in encouraging manufacturers to think seriously about
switching OTC products back to prescription status.
Finally, retailers also may face enhanced exposure to liability after an
Rx-to-OTC switch.  Pharmacists encounter only limited liability in selling
prescription products, but pharmacies and other businesses that sell non-
prescription drugs face the same strict liability imposed on retailers of reg-
ular consumer goods.189  Indeed, retailers enjoy greater flexibility than
OTC drug manufacturers when it comes to restricting consumer access to
such products, as demonstrated by chains that opted for behind-the-
counter sales of drugs containing pseudoephedrine before that became
mandatory.190  Thus, if they fail to adopt such point-of-purchase safe-
guards, then this class of potential defendants may face negligent market-
ing claims, and they would not get the benefit of an implied preemption
defense because the FDA hardly exercises any control over nonprescrip-
tion drug product retailers.
V. CONCLUSION
Once a prescription drug has transitioned into the nonprescription
marketplace, a variety of factors conspire against moving it back.  Instead,
as worrisome additional hazards of use come to light, the FDA simply
(Calabresi, J., dissenting) (“Selling tanks to the armed forces is fine; selling them
to the general public is, I would think, clearly negligent.”).
187. See 21 U.S.C. § 353(b)(4)(B) (2012); 21 C.F.R. § 310.200(d) (2018).
188. See Mutual Pharm. Co. v. Bartlett, 570 U.S. 472, 484–87, 490–92 (2013).
189. See, e.g., Morales v. Am. Home Prods. Corp., 214 F. Supp. 2d 723, 726
(S.D. Tex. 2002); see also RESTATEMENT (THIRD) OF TORTS: PRODS. LIAB. § 6(e) &
cmt. h (1998); David J. Marchitelli, Annotation, Liability of Pharmacist Who Accurately
Fills Prescription for Harm Resulting to User, 44 A.L.R.5th 393 (1996 & 2017 Supp.).
190. See supra note 159 and accompanying text; see also Joyce Gemperlein, Ask
the Pharmacists; Why Are Nonprescription Items Behind the Counter?, WASH. POST, Dec.
25, 2005, at Z6.  Only once before has the manufacturer of an OTC drug tried to
create (and then only temporarily) a behind-the-counter system of distribution.
See Francesca Lunzer Kritz, Over the Counter but Not Easy to Reach, WASH. POST, Oct.
8, 2002, at F3 (Mucinex® (guaifenesin)).
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shares the new risk information with consumers.  In spite of evidence that
laypersons pay little or no attention to such disclosures, and the mounting
injuries suffered by consumers, the agency persists in its unproductive
strategy of larding up product labels rather than reconsidering the wisdom
of its original judgment to authorize OTC availability.191  This represents a
serious public health problem that deserves more than the passing atten-
tion it has received to date.  Although tort litigation might serve as a par-
tial counterweight to manufacturers’ lack of incentives to request a return
to prescription status, judicial resistance to negligent marketing claims
coupled with receptivity to the preemption defense severely limit this pros-
pect.  In the absence of a greater willingness by the FDA to confront this
issue (or some sort of broad-based legislative reforms designed to facilitate
such a process), the dangers associated with giving consumers largely un-
supervised access to powerful pharmaceutical agents have become largely
intractable.
191. Cf. Noah, The Imperative to Warn, supra note 34, at 398 (“If the goal is to
influence behavior and deter use of a product without entirely constraining free-
dom of choice, alternatives to labeling might include . . . prescription require-
ments of different stringency.”).
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